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ABSTRACT 
 
Characterization of Murine Cardiac Cholinergic Innervation and its Remodeling  
 
in Type 1 Diabetes 
 
by  
 
Abigail M. Mabe 
 
Murine models have become increasingly popular to study various aspects of 
cardiovascular diseases due to their ease of genetic manipulation. Unfortunately, there 
has been little effort put into describing the distribution of autonomic nerves in the 
mouse heart, making it difficult to compare current findings from clinical and 
experimental models related to cardiovascular diseases. Furthermore, determination of 
the requirements for the development of this system and its maintenance in adult mice 
remains largely unexplored. This study represents the first detailed mapping of 
cholinergic neuroanatomy of the mouse heart based on immunohistochemical staining 
using true cholinergic markers. We found cholinergic innervation of the mouse heart to 
be largely focused in the atrium and conducting system. We investigated the 
involvement of the neurotrophic factor neurturin (NRTN) in the development of 
cholinergic innervation, because there was indirect evidence that implicated it as a 
crucial factor. Results from our work definitively demonstrate that NRTN plays a major 
role in the development of cardiac parasympathetic ganglia and cholinergic innervation 
of the mouse heart.  Adult NRTN knockout mice exhibited a drastic reduction in the 
number of intracardiac neurons with decreased atrial acetylcholine, cholinergic nerve 
density at the sinoatrial node and negative chronotropic responses to vagal stimulation. 
The presence of NRTN and its receptors in hearts from adult wild-type mice suggests 
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that this neurotrophic factor might also be required for maintenance of cardiac 
cholinergic innervation. Finally, we wanted to determine how intracardiac neurons and 
their processes change during diseased states, specifically type 1 diabetes. This work 
has shown that the cardiac cholinergic nervous system in the mouse undergoes 
structural and functional remodeling when challenged with streptozotocin-induced 
diabetes. Cholinergic nerves in diabetic hearts undergo extensive sprouting at the 
sinoatrial node with no change in the number of intracardiac neurons. Cholinergic 
function appears to be enhanced in diabetic mice, based on pharmacological testing, 
despite decreased response to direct vagal nerve stimulation.  Evidence also suggests 
that diabetic mice have an imbalance in autonomic control of heart rate.  The latter 
findings suggest that disruption of central input into intrinsic cardiac ganglia also 
contributes to the neuropathology of type 1 diabetes.  
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CHAPTER 1 
 
INTRODUCTION 
 
Autonomic Nervous System and Control of the Heart 
  The autonomic nervous system (ANS) is a subdivision of the peripheral nervous 
system that acts to maintain homeostasis in the body.  In general, these activities are 
performed without conscious control.  The ANS assists in regulation of numerous bodily 
functions including heart rate (HR), blood pressure, respiration rate, perspiration and 
many others. Autonomic control of the heart is accomplished via two antagonistic 
branches of the ANS, the sympathetic and the parasympathetic, that modulate the 
intrinsic pacemaker activity of the heart.   
  Parasympathetic control of the heart includes regulation of HR and the 
conduction system.  Parasympathetic innervation of the heart is accomplished by the 
vagus nerve. Central stimulation of the vagus results in the release of acetylcholine 
(ACh) from post-ganglionic cholinergic nerve endings at the sinoatrial (SA) node. Once 
released, the ACh binds to post-junctional muscarinic receptors (M2) on SA node 
myocytes to decrease HR. Activation of muscarinic receptors is important for returning 
cardiac function to baseline after sympathetic activation by reducing HR, contractile 
force of atrial cardiac muscle and conduction velocity through the atrioventricular (AV) 
node, bundle of His and bundle branches. In large animals and humans with a lower 
resting HR, the HR is controlled by the parasympathetic nervous system under normal 
conditions, when the intrinsic firing rate of the SA node is decreased by vagal input.   
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  Sympathetic control of the heart is accomplished through pre- and post-
ganglionic synapses within the sympathetic nervous system. Preganglionic sympathetic 
neurons release ACh, which then binds to nicotinic ACh receptors on postganglionic 
neurons. In response to a stimulus, postganglionic neurons release norepinephrine 
(NE). The NE then binds to adrenergic receptors, termed beta 1 (β1), in the SA node to 
increase HR.  Activation of β1-adrenergic receptors also mediates increased 
contractility of atrial and ventricular cardiac muscle, increased cardiac output and 
automaticity.  
 
Impact of Cardiovascular Diseases on Autonomic Control of the Heart 
  In order to achieve normal cardiovascular function, there must be a balance 
between sympathetic and parasympathetic inputs to the heart (Moravec 2008). In 
certain cardiovascular diseases an imbalance between the two branches causes 
manifestation of the disease and often contributes to its progression. Imbalance within 
the ANS has been observed in several cardiovascular diseases including hypertension, 
heart failure, and diabetes (Curtis and O'Keefe, Jr. 2002; Brook and Julius 2000; 
Machado et al. 2000; Meredith et al. 1993; Esler 2000; Jermendy 2003; Oberhauser et 
al. 2001). The presence of autonomic imbalance implies that one branch has 
inappropriate domination over the other, which has been viewed as a lack of “dynamic 
flexibility and health” (Thayer and Lane 2007).  Typically, sympathetic tone becomes 
increased and/or parasympathetic (vagal) tone decreased (Thayer and Lane 2007).  
  A central theme within the autonomic imbalances observed in cardiovascular 
disease is decreased vagal function. A reduction in vagal activity shifts the balance of 
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autonomic control in favor of sympathetic nerves. Remodeling of this nature is very 
unfavorable because dominant sympathetic activity could increase the automaticity of 
the ventricles, thereby increasing risk for development of arrhythmias (Hjalmarson 1980; 
Kent and Epstein 1976). Decreased vagal inhibitory influence can be identified in 
several ways including increased HR, decreased heart rate variability (HRV), decreased 
HR recovery following exercise or decreased baroreflex sensitivity, as well as many 
others, all of which are associated with increased risk for cardiovascular disease and 
mortality (Thayer and Lane 2007). In patients with acute myocardial infarction (MI), an 
autonomic imbalance has been found to result in excessive elevation in blood pressure 
and HR during exercise training (Matsunaga et al. 2004).  
  Changes to the sympathetic nervous system with respect to autonomic 
imbalance are especially evident in cases of heart failure.  Patients with congestive 
heart failure (CHF) have decreased cardiac tissue levels of the sympathetic 
neurotransmitter NE with a loss of cardiac sympathetic nerve fibers despite increased 
sympathetic nerve firing and circulating NE levels (Machado et al. 2000; Meredith et al. 
1993). These changes have also been observed in patients with essential hypertension 
(Esler 2000).  Increased sympathetic activation in CHF has been shown to contribute to 
adverse cardiac remodeling, including apoptosis of myocytes, cause down-regulation of 
β1 adrenergic receptors, and decrease or abolish inotropic and chronotropic responses 
to NE and other catecholamines (Kaye and Esler 2005; Lohse et al. 2003).  The 
increased activation of sympathetic nerves in patients with heart failure has been shown 
to contribute to poor prognosis and is associated with even more severe heart failure 
(Kaye et al. 1995).   
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Several studies have suggested that autonomic imbalance, such as that 
observed in cardiovascular diseases, may be due to a disruption of central input into the 
cardiac ANS (Thayer and Lane 2007; Benarroch 1993; Spyer 1989). These studies 
found that when central inhibitory pathways involving the neurotransmitter γ-
aminobutyric acid (GABA) were interrupted, hypertension and sinus tachycardia 
resulted.  
 
Neurotrophic Influences on Cardiac Innervation 
  Impaired vagal control in cardiovascular diseases is often assumed to be a 
consequence of cholinergic nerve damage and denervation caused by the disease 
(Maser and Lenhard 2005).  However, there has been little effort made to investigate 
this hypothesis. Neurotrophic factors have been implicated in the nerve changes 
associated with cardiovascular diseases since they are responsible for growth and 
survival of neurons and their processes during development, and some are required for 
maintenance of adult sympathetic and sensory neurons (Habecker et al. 2008; Kimura 
et al. 2007; Mattson and Wan 2008; Mendell 1999; Davies 1996). Noradrenergic 
activation has been linked to a decrease in nerve growth factor (NGF) expression in 
cardiac myocytes (Kaye et al. 2000; Qin et al. 2002). Deficiency of this neurotrophic 
factor causes a loss of NE transporters from sympathetic nerves and potential 
regression of sympathetic fibers (Kaye and Esler 2005).  Conversely, elevated NGF 
levels around infarcted myocardium were associated with regional sympathetic nerve 
sprouting (Chen et al. 2001; Oh et al. 2006; Cao et al. 2000b; Cao et al. 2000a). These 
studies suggest a strong link between sympathetic nerve changes in cardiac disease 
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and neurotrophic factors; however, the trophic factor requirements for survival and 
maintenance of cardiac parasympathetic neurons are largely unknown. 
 
Diabetes and Cardiac Autonomic Control 
  Impaired autonomic regulation of the heart occurs in patients with diabetes and is 
found to be associated with poor prognosis.  The presence of autonomic imbalance 
increases the risk for developing life threatening ventricular arrhythmias and sudden 
death (Vinik et al. 2003). Several epidemiological studies have provided evidence that 
diabetes also increases the risk for atrial fibrillation, which often impairs quality of life 
and can lead to stroke (Movahed et al. 2005; Vinik et al. 2003). The mechanisms 
underlying these associations are undoubtedly complex and most likely involve 
pathophysiological remodeling of the ANS and cardiac tissue.   
  Results from several studies of clinical diabetes indicate dysfunction of the 
cardiac ANS and remodeling of its structure and function.  Cholinergic nerve damage 
and denervation have been thought to be the cause of the impaired vagal control of 
heat rate in diabetics (Maser et al. 2003; Vinik et al. 2003; Vinik and Ziegler 2007), but 
this theory has not been explored experimentally. Several clinical studies have used 
HRV measurements to assess parasympathetic and sympathetic control of the sinus 
node in patients with and without diabetes (Burger et al. 1999; Molon et al. 2006; Singh 
et al. 2000). In human diabetics, decreased HRV is considered to be the earliest sign of 
cardiac dysfunction (Kardelen et al. 2006; Javorka et al. 2005). This, in combination with 
decreased cardiac baroreflex observed in type 1 diabetics, has been attributed to 
cardiac parasympathetic denervation (Vinik and Ziegler 2007). ACh release and choline 
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uptake were decreased in atrial appendage taken from diabetic patients with poor 
glycemic control and late complications (neuropathy, nephropathy), which is suggested 
as being consistent with a loss of nerves (Vinik and Ziegler 2007; Oberhauser et al. 
2001; Maser and Lenhard 2005). However, there has been little attempt to look at the 
nerves themselves to support this idea of parasympathetic denervation. Functional 
impairment of cardiac sympathetic nerve fibers has been observed in patients with type 
1 diabetes and attributed as a major cause of inadequate cardiac contraction response 
during exercise (Scognamiglio et al. 1998). Examination of post-mortem cardiovascular 
tissue of diabetics found decreased levels of NE as well (Neubauer and Christensen 
1976).  Additionally, impairment of noradrenergic uptake has been observed in diabetic 
patients based on 123I-metaiodobenzylguanidine uptake studies (Langer et al. 1995; 
Scognamiglio et al. 2000) 
Autonomic dysfunction of the cardiovascular system has also been found in 
experimental animal models of type 1 diabetes. The majority of these studies were 
performed on animals (usually rats or mice) treated with streptozotocin (STZ). This drug 
is accumulated selectively by pancreatic beta cells and causes cell death in a 
substantial portion of this population (Szkudelski 2001). Diabetic rats and pigs treated 
with STZ have decreased HRV and impaired baroreflex sensitivity (Howarth et al. 
2005b; Howarth et al. 2006; Mesangeau et al. 2000; Dall'Ago et al. 2007).  These 
changes mimic effects seen in human diabetics and suggest that diabetic animals also 
have impaired parasympathetic control of HR. Unlike patients with type 1 diabetes, 
resting HR is depressed in STZ-treated rats, which has been attributed in part to an 
effect on the intrinsic pacemaker (Howarth et al. 2005b; Howarth et al. 2005a).  
 20
Cardiac sympathetic remodeling in diabetes has been studied extensively using 
the STZ rat model.  Within the first 2 months of disease, cardiac NE levels were 
increased (Akiyama et al. 1989; Felten et al. 1982), which could be due to increased 
NGF expression followed by sprouting of noradrenergic nerve fibers (Hellweg and 
Hartung 1990; Rohrer et al. 1996). NE turnover and stimulation-evoked release in 
isolated atria tissue are also increased at this time (Ganguly et al. 1986). Early 
increases in noradrenergic innervation are followed by significant regional decreases in 
NE levels, which are present between 6 and 12 months after STZ treatment (Rohrer et 
al. 1996). Reduction of NE levels is most likely a consequence of decreased NGF 
expression, which has been demonstrated in the distal left ventricle after 9 months of 
diabetes and was associated with a loss of sympathetic nerve fibers (Rohrer et al. 
1996). Nerve degeneration, likely preganglionic, has also been observed in intrinsic 
cardiac ganglia from STZ-treated rats after 1 year of diabetes, yet the postganglionic 
cell bodies themselves appeared normal (Kamal et al. 1991). Furthermore, electron 
microscopy studies on alloxan-treated rats showed a loss of atrial post-ganglionic 
cholinergic nerves which is consistent with their loss in function after 7-8 months of 
diabetes (Tomlinson and Yusof 1983).  
 
Specific Aims 
Murine models have become increasingly more popular in the study of various 
aspects of cardiovascular diseases due to their ease of genetic manipulation. 
Unfortunately, there has been little effort put into describing the distribution of autonomic 
nerves in the mouse heart, making it difficult to compare with findings from previous 
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clinical and experimental models related to cardiovascular diseases. Of the few studies 
involving cholinergic innervation of the heart in rodents, none have been carried out 
using true cholinergic markers such as choline acetyltransferase (ChAT), choline 
transporter (CHT), or vesicular ACh transporter (VAChT). Furthermore, determination of 
the requirements for the development of this system and its maintenance in adult mice 
remains largely unexplored. In order to address these deficits, the first aim of this study 
was to truly define the anatomy of the cardiac cholinergic nervous system in the mouse. 
These findings have been published in Cell & Tissue Research and are discussed in 
Chapter 2. To further address the deficits in knowledge about cholinergic innervation of 
the mouse, the second aim of this study was to investigate the involvement of the 
neurotrophic factor neurturin (NRTN) because there was indirect evidence that 
implicated it in cardiac cholinergic development of neonatal mice. Specifically, we 
wanted to define expression of NRTN and its receptors in adult hearts and determine 
the impact of developmental NRTN deficiency on cholinergic structure and function in 
adult hearts. These experiments are contained within Chapters 2 and 3 and show 
potential ability for plasticity and remodeling of cardiac cholinergic innervation. The final 
aim of this study was to determine how intracardiac neurons and their processes 
change during diseased states, specifically type 1 diabetes. There is evidence for 
sympathetic trophic factor influences on cardiac innervation during cardiovascular 
disease, especially in heart failure. Additional evidence suggests decreased vagal tone 
in cardiovascular diseases such as hypertension and diabetes. Indirect evidence 
through HR and HR dynamics suggests decreased vagal tone in type 1 diabetes, with 
no direct investigation into the neuroanatomy and function of the system itself.  
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Accordingly, the main focus of the final aim, addressed in Chapter 4, was to determine 
the impact of experimental type 1 diabetes on cholinergic structure and function of the 
mouse heart. 
 
 
 23
CHAPTER 2 
 
 
LOCALIZATION OF CHOLINERGIC INNERVATION AND NEURTURIN RECEPTORS 
IN ADULT MOUSE HEART AND EXPRESSION OF THE NEURTURIN GENE 
 
 
Abigail M. Mabe, Jennifer L. Hoard, Michelle M. Duffourc, Donald B. Hoover* 
 
 
 
 
Department of Pharmacology, James H. Quillen College of Medicine 
 East Tennessee State University, Johnson City, TN 37614-1708, USA 
 
*Corresponding Author: Dr. Donald B. Hoover, Department of Pharmacology, P.O. Box 
70577, James H. Quillen College of Medicine, East Tennessee State University, 
Johnson City, TN 37614-1708  
E-mail address: hoover@mail.etsu.edu 
 
Running title: Neurturin & cholinergic innervation in adult mouse heart 
 
Keywords: Choline acetyltransferase, High affinity choline transporter, Cardiac 
parasympathetic ganglia, GFRα2, Ret 
 
 
Copyright notice: With kind permission from Springer Science+Business Media: Cell 
and Tissue Research, Localization of cholinergic innervation and neurturin receptors in 
adult mouse heart and expression of the neurturin gene, volume 326, 2006, pages 57-
67, Abigail M. Mabe, Jennifer L. Hoard, Michelle M. Duffourc, Donald B. Hoover. 
 24
Abstract 
  Neurturin (NRTN) is a neurotrophic factor required during development for 
normal cholinergic innervation of the heart, but whether NRTN continues to function in 
the adult heart is unknown. We have therefore evaluated NRTN expression in adult 
mouse heart and the association of NRTN receptors with intracardiac cholinergic 
neurons and nerve fibers. Mapping the regional distribution and density of cholinergic 
nerves in mouse heart was an integral part of this goal. Analysis of RNA from adult 
C57BL/6 mouse hearts demonstrated NRTN expression in atrial and ventricular tissue. 
Virtually all neurons in the cardiac parasympathetic ganglia exhibited the cholinergic 
phenotype, and over 90% of these cells contained both components of the NRTN 
receptor, Ret tyrosine kinase and GDNF family receptor α2 (GFRα2). Cholinergic nerve 
fibers, identified by labeling for the high affinity choline transporter, were abundant in the 
sinus and atrioventricular nodes, ventricular conducting system, interatrial septum, and 
much of the right atrium, but less abundant in the left atrium. The right ventricular 
myocardium contained a low density of cholinergic nerves, which were sparse in other 
regions of the working ventricular myocardium. Some cholinergic nerves were also 
associated with coronary vessels. GFRα2 was present in most cholinergic nerve fibers 
and in Schwann cells and their processes throughout the heart. Some cholinergic nerve 
fibers, such as those in the sinus node, also exhibited Ret immunoreactivity. These 
findings provide the first detailed mapping of cholinergic nerves in mouse heart and 
suggest that the neurotrophic influence of NRTN on cardiac cholinergic innervation 
continues in mature animals.
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                                                           Introduction 
  Autonomic regulation of the heart is accomplished through noradrenergic 
sympathetic nerves and cholinergic parasympathetic nerves that innervate the 
myocardium (Ardell 2004). Cardiac sympathetic nerve fibers project from noradrenergic 
neurons located in specific paravertebral ganglia (e.g., stellate ganglia), while 
parasympathetic fibers come from cholinergic neurons located in the intracardiac 
ganglia (Ardell 2004; Hoover et al. 2004; Parsons 2004). Sympathetic neurons are 
known to have a lifelong requirement for nerve growth factor (NGF), which is supplied 
by target tissues (e.g., myocardium) and transported back to cell bodies in the ganglia 
via noradrenergic nerve fibers (Gorin and Johnson 1980; Thoenen et al. 1987). In adult 
animals, NGF plays a crucial role in regulating the density of cardiac sympathetic 
innervation; a deficiency of NGF causes the loss of noradrenergic nerve fibers, whereas 
excessive amounts of NGF cause hyperinnervation (Gorin and Johnson 1980; 
Hassankhani et al. 1995; Qin et al. 2002; Ieda et al. 2004). Recent studies have 
demonstrated that such changes can occur in cardiac disease and produce adverse 
remodeling of noradrenergic innervation (Cao et al. 2000; Kaye et al. 2000). Less is 
known regarding the trophic factor requirements of intracardiac neurons (i.e., 
parasympathetic neurons), but neurturin (NRTN) is a promising candidate (Heuckeroth 
et al. 1999; Rossi et al. 1999; Hiltunen et al. 2000; Airaksinen and Saarma 2002). NRTN 
is a member of the glial-cell-line-derived neurotrophic factor (GDNF) family, which also 
includes GDNF itself, persephin, and artemin (Airaksinen and Saarma 2002). These 
factors differ substantially from the neurotrophins (e.g., NGF) in structure and signaling 
mechanism but share the attributes of being target-derived proteins and of supporting 
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the development, survival, and maintenance of specific populations of peripheral 
neurons. Members of the GDNF family signal through multicomponent receptors that 
contain the transmembrane tyrosine kinase, Ret, and one of four GDNF family receptors 
(GFRα1–GFRα4). Each neurotrophic factor of the GDNF family has been shown to 
signal preferentially through a specific GFRα. For example, GDNF preferentially signals 
through GFRα1/Ret and NRTN via GFRα2/Ret, but some crosstalk can occur in vitro at 
higher ligand concentrations (Airaksinen and Saarma 2002). Specifically, NRTN can 
signal through GFRα1/Ret, and GDNF can signal via GFRα2/Ret. However, current 
evidence suggests that each of the trophic factors interacts specifically with its preferred 
receptor in vivo (Leitner et al. 1999; Airaksinen and Saarma 2002; Paveliev et al. 2004). 
  Several investigators have included the heart in studies involving in situ 
hybridization to define the regional expression of NRTN, Ret, and GDNF family 
receptors in the central nervous system and periphery of mice (Widenfalk et al. 1997; 
Golden et al. 1999). These experiments have provided evidence that NRTN is 
expressed in the myocardium from embryonic day 12 through the first postnatal week, 
but no signal has been detected in adult heart. Although intracardiac ganglia have not 
been included in these studies, another group has reported that high levels of Ret and 
GRFα2 mRNAs occur in parasympathetic ganglion neurons of E18, P21, and P60 rat 
hearts (Hiltunen et al. 2000). Ret expression is exclusive to intracardiac neurons, 
whereas low levels of GFRα2 mRNA are also associated with adventitial and valvular 
cells. These results suggest that both components of the NRTN receptor are present in 
intracardiac neurons of embryonic and adult rats. Neither GFRα1 nor GFRα3 has been 
detected in intracardiac neurons, but low to moderate levels are associated with glial 
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cells in the parasympathetic ganglia. Further studies conducted with ret knockout mice, 
which die shortly after birth, have shown that their hearts contain approximately half the 
number of neurons as wild type mice (Hiltunen et al. 2000). In addition, cholinergic 
innervation of the conducting system is absent or clearly reduced in ret knockout mice. 
Significant decreases in the density of cholinergic nerves in the right ventricular 
myocardium and the conducting system also occur in adult gfrα2 knockout mice. 
Collectively, these findings suggest that NRTN is required for the normal development 
of cardiac parasympathetic ganglia and the normal cholinergic innervation of the heart 
(Hiltunen et al. 2000). 
  Whereas current evidence supports a role for NRTN in the development of 
cardiac parasympathetic ganglia and cholinergic innervation of specific regions of the 
heart, little is known about NRTN expression in the adult heart or about the extent of 
NRTN receptor association with intracardiac cholinergic neurons and nerve fibers. 
Likewise, the distribution of cholinergic nerves within the mouse heart has not been 
mapped in detail. Therefore, we have used reverse transcription with the polymerase 
chain reaction (RT-PCR) to evaluate nrtn expression in atrial and ventricular tissue from 
adult mice. The regional localization of cholinergic neurons and nerve fibers in adult 
mouse heart and the association of GFRα2 and Ret with cholinergic innervation have 
been determined by fluorescence immunohistochemistry. 
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Materials and methods 
Animals  
  Hearts (n=15) were obtained from adult male C57BL/6 mice (Harlan, 
Indianapolis, IN) (24-30g) anesthetized with sodium pentobarbital (90mg/kg, i.p.).  
Animal protocols were approved by the East Tennessee State University Animal Care 
and Use Committee and conformed to guidelines of the National Institutes of Health 
published in the Guide for the Care and Use of Laboratory Animals (NIH publication No. 
85-23, revised 1996).   
 
RNA Extraction and Quantification 
  Total RNA from entire atria (including right and left atrium and interatrial septum) 
and left ventricular free wall was extracted using the RNeasy Fibrous Tissue kit and 
DNase I treatment according to the manufacturer’s protocol (QIAGEN Inc., Valencia, 
CA).  The RNA yield and purity were determined by measuring the absorbance ratio at 
260/280 nm (>1.9) on an Eppendorf BioPhotometer. 
 
RT-PCR analysis  
  First-strand cDNA was synthesized from 1 µg of total RNA and 0.5 µg anchored 
oligo(dT)20 (Integrated DNA Technologies, Inc., Coralville, IA) using Superscript II 
reverse transcriptase (Invitrogen, Carlsband, CA).  Commercially available first-strand 
cDNAs from total heart and stomach of 8 week old normal mice (BioChain Institute, Inc., 
Hayward, CA) were used as positive control templates.  Control experiments were 
performed in the absence of reverse transcriptase to exclude the possibility of 
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amplification from contaminating genomic DNA.  NTRN cDNA was amplified using the 
sense primer 5’-CTCCCTG CTATCTGTCTGGATGTGC-3’ and antisense primer 5’-
TCTCATCCGACGTGTA GCCCAG-3’ to yield a 320 bp PCR product.  Each PCR 
reaction (25 µL) consisted of 2.5 μL 10X Taq buffer, 2.5 μL 2.0 mM dNTPs, 1.25 μL 
DMSO, 20 pmol of primers, 1μL cDNA template, and 0.25μL MasterTaq DNA 
Polymerase (Eppendorf, Westbury, NY).  PCR was performed under the conditions of 
one cycle at 94°C for 2 min, 35 cycles at 94°C for 15 s, 55°C for 30 s, and 72°C for 45 
s, followed by a final extension at 72°C for 9.5 min.  β-actin was used as an internal 
standard along with commercially available primers (BioChain Institute, Inc., Hayward, 
CA).  PCR products were electrophoresed on 1.5% agarose gels and visualized using 
ethidium bromide staining.  Band intensity was quantified on a BioRad FX 
phosphorimager using Quantity One software (Bio-Rad Laboratories, Inc., Philadelphia, 
PA).  The identity of the PCR products was confirmed by sequencing on both strands.   
 
Tissue processing for histology  
  Hearts were was obtained from deeply anesthetized mice and placed briefly in 
phosphate buffered saline (PBS) (pH 7.4) to remove blood.  They were then fixed for 2 
hours in cold PBS containing 4% paraformaldehyde and 0.2% picric acid, cryoprotected 
for 2 days in cold 20% sucrose/PBS, and sectioned in an IEC cryostat/microtome.  In a 
few cases, the ascending aorta was cannulated to enable brief perfusion fixation of the 
heart before it was placed in cold fixative.  Serial 30μm short-axis sections were 
collected in three sets beginning at the most anterior aspect of the heart and ending at a 
level well into the ventricular myocardium.  For a few hearts, six sets of 15μm sections 
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were collected.  Each set of slides was boxed separately, wrapped in aluminum foil, and 
stored at -80°C.  
 
Immunohistochemistry  
  Slide mounted tissue sections were immunostained at room temperature.  Briefly, 
sections were washed in 0.1M PBS (pH 7.3), permeabilized with 0.4% Triton X-100 in 
PBS containing 0.5% bovine serum albumin (BSA), and blocked for 2 hours in PBS 
containing 10% normal donkey serum (Jackson ImmunoResearch Laboratories, West 
Grove, PA), 1% BSA, and 0.4% Triton X-100.  Tissues were then incubated for 15-18 
hours with two primary antisera generated in different species (Table 1), washed 
several times with 0.1M PBS, and incubated for 2 hours with species specific donkey 
secondary antibodies conjugated to Alexa Fluor 488 or 555 (Molecular Probes, Eugene, 
OR). All secondary antibodies were used at a dilution of 1:200.  After washing the 
sections several times with PBS, coverglasses were attached using Citifluor mounting 
medium (Ted Pella, Inc., Redding, CA) and sealed with clear nail polish.  Some sections 
were routinely processed without primary antibodies as a negative control.   
 
Image Analysis and Confocal Microscopy 
  Labeled tissue sections were viewed and photographed using an Olympus BX41 
microscope equipped with an Optronics MagnaFire SP CCD camera and regions of 
interest selected for further evaluation by confocal microscopy.  Fluorescence 
microscopic images of intracardiac ganglia were evaluated using Stereo 
Investigator/Workstation software (MicroBrightField, Inc., Williston, VT) to quantify 
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labeled neurons. The total number of neurons present in each section was determined 
based on staining for the pan-neuronal marker, protein gene product 9.5 (PGP 9.5).  
The percentage of these neurons that also stained for Ret or GRFα2 was determined in 
double labeling experiments.  Confocal images of selected tissue regions were collected 
using a Leica TCS SP2 confocal microscope system.  Specimens were scanned 
sequentially to avoid crosstalk between fluorochromes, and a maximum projection 
image was obtained from each series.  Negative controls for each fluorochrome were 
also scanned using the same parameter settings.  Images were exported into Corel 
Draw 11 and adjusted for brightness and contrast.   
 
Results 
Presence of NRTN mRNA in adult mouse heart 
To begin investigation of NRTN expression in the adult mouse heart, we 
performed PCR analysis using cDNA from whole heart as well as stomach, an 
established positive control tissue (Golden et al. 1999). As shown in Fig. 2.1 A, PCR 
produced identically sized amplimers from both tissues. Sequence analysis of the 
products revealed that they matched a 320 base pair region of murine NRTN (392-
712bp; GenBank accession NM00873), thus confirming their identity. Based upon these 
findings, we next evaluated regional expression of NRTN. RT-PCR was carried out on 
total RNA isolated from total atrium and the left ventricular free wall.  Comparison of 
band intensities normalized to β-actin levels demonstrated that the abundance of NRTN 
mRNA in atria did not differ significantly from that in left ventricular wall (Fig. 2.1 B,C). 
Comparable results were obtained when the same cDNA samples were evaluated using 
mouse beta-2-microglobulin mRNA levels for normalization. Neither β-actin nor beta-2-
microglobulin mRNA levels varied appreciably between samples (data not shown). 
 
Fig. 2.1. NRTN is expressed by adult mouse heart.  
PCR analysis of whole heart (H) cDNA and 
stomach (S) cDNA (positive control) from an adult 
mouse resulted in a 320bp product with a 
sequence identical to 392-712bp of murine NRTN 
(A).  RT-PCR analysis of mRNAs obtained from 
total atrium (A) and left ventricular (LV) wall 
established that NRTN expression occurred in 
both regions of the heart (B).  NRTN band 
intensities were expressed as a percentage of 
beta-actin band intensities for the same samples 
(C).  Values for atria and left ventricle (mean ± SE, 
n=3) are not significantly different (paired t-test, 
P>0.05). 
 33
Localization of GFRα2 & Ret to neuronal cell bodies in intracardiac ganglia 
  Parasympathetic ganglia were identified initially in sections of mouse heart 
immunostained for PGP 9.5 to visualize all neurons and for choline acetyltransferase 
(ChAT) to identify cholinergic neurons.  These ganglia were located primarily in 
epicardial connective tissue along the posterior surface of the atria.  A vast majority of 
the PGP 9.5-positive somata in the intracardiac ganglia exhibited ChAT 
immunoreactivity (Fig. 2.2 A,B), indicating that they are cholinergic neurons.  Similar 
staining for PGP 9.5 and each NRTN receptor component showed that most 
intracardiac neurons exhibit GFRα2 and Ret immunoreactivity (Fig. 2.2 C-F).  
Quantitative evaluation of double-labeled sections from three hearts demonstrated that 
94 ± 1% (mean ± SE) of intracardiac neurons (534 ± 168 PGP 9.5 labeled neurons 
counted per heart) contained GFRα2 immunoreactivity and 93 ± 3% stained for Ret 
(487 ± 184 PGP 9.5 labeled neurons counted per heart).  Therefore, most intracardiac 
neurons of the mouse contain the specific cholinergic marker ChAT and both 
components of the NRTN receptor.   
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Fig. 2.2.  Most neurons of adult mouse intracardiac ganglia contain ChAT, GFRα2 and 
Ret.  Sections of mouse heart were double immunolabeled for the pan-neuronal marker 
PGP 9.5 and either ChAT (cholinergic marker), GFRα2 or Ret.  Panels show 
sequentially scanned confocal images of intracardiac ganglia.  The vast majority of PGP 
9.5 immunoreactive neuronal cell bodies also demonstrate ChAT immunoreactivity (A, 
B), GFRα2 immunoreactivity (C, D) and Ret immunoreactivity (E, F).  Images are single 
optical sections.  Scale bars = 80 µm
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Localization of GFRα2 to cholinergic nerve fibers and Schwann cells. 
 
  The localization of GRFα2 immunoreactivity to a high proportion of intracardiac 
cholinergic neurons suggests that this component of the NRTN receptor should be 
present in cholinergic nerves throughout the heart.  This premise was tested by 
evaluating the colocalization of GFRα2 and high affinity choline transporter (CHT) 
immunoreactivity in short-axis sections of heart beginning at a level anterior to the sinus 
node and ending in the ventricular myocardium about 2 mm below the atrioventricular 
(AV) valves.  Confocal analysis of these sections established that GFRα2 
immunoreactivity was highly associated with CHT-positive cholinergic nerve fibers 
throughout their distribution in the atria, the AV conducting system, and ventricular 
tissue.  Highest densities of CHT/GFRα2 positive nerve fibers occurred in the sinus 
node (Fig. 2.3 A-C), interatrial septum (Fig. 2.3 D-F), AV node (Fig. 2.3 G-I), ventricular 
conducting system and atrial muscle near the AV junction (Fig. 2.4 A-C).  Other regions 
of right atrial myocardium contained a high to moderate density of dual-labeled fibers 
(Fig. 2.4 D-F), and the overall abundance of cholinergic nerve fibers in left atrium was 
less than in the right (Fig. 2.4, compare D-F to G-I).  A low density of CHT/GFRα2 
positive nerve fibers was seen in right ventricular myocardium (Fig 2.5 A-C) but 
cholinergic innervation was sparse in the ventricular septum and left ventricular free wall 
(Fig. 2.5 D-F). Lastly, some CHT/GFRα2 positive nerve fibers occurred in atrial and 
ventricular epicardium, AV valves and around coronary arteries of various sizes (Figs. 
2.4 D-F and 2.5 A-C). 
  While there was extensive colocalization of GFRα2 and CHT in many nerve 
fibers, a few cholinergic nerves did not show GFRα2 immunoreactivity (Fig. 2.4 D-F).  It 
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was noted also that staining for GFRα2 often extended beyond the cholinergic nerve 
fibers that were identified by labeling for CHT (e.g., Fig. 2.3 & 2.4, solid arrowheads).  
Furthermore, GFRα2 immunoreactivity was evident in some non-cholinergic fiber 
bundles (e.g., asterisks in Fig. 2.4) and processes.  Such labeling was very evident in 
the left ventricular wall where cholinergic nerves were sparse (Fig. 2.5D-F).  Since 
GFRα2 has been identified in Schwann cells in other tissues (Rossi et al., 2003; 
Wanigasekara et al. 2004), additional double labeling experiments were done using 
antibodies to the Schwann cell marker S100 and to GFRα2. These experiments showed 
that Schwann cells and their processes were common in the left ventricular wall (Fig. 
2.6 A-F) and in other regions of atrial and ventricular myocardium. A vast majority of 
these glial cells and their processes also stained for GFRα2 (Fig. 2.6 A-F).  Double 
labeling for S100 and the vesicular ACh transporter (VAChT), another cholinergic 
marker, further demonstrated that Schwann cells and their processes often occurred 
adjacent to cholinergic nerve fibers (Fig. 2.6 G-I). Satellite cells of the cardiac 
parasympathetic ganglia also stained intensely for S100 but did not exhibit GFRα2 
immunoreactivity (not shown).  
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Fig. 2.3.  GFRα2 immunoreactivity associated with dense cholinergic innervation of 
cardiac nodal tissue and the interatrial septum.  Panels show sequentially scanned 
confocal images of tissue sections that were double immunolabeled for CHT (red) and 
GFRα2 (green).  Extensive colocalization of these markers (yellow in right panels) was 
observed in the sinus node (A-C), interatrial septum (D-F) and AV node (G-I). Arrows 
indicate examples of colocalization. Arrowheads indicate examples of probable 
Schwann cell elements labeled for GFRα2 only.  Panels A-F are maximum projection 
images obtained from 26 optical sections spanning a tissue thickness of 10 µm.  Panels 
G-I are single optical sections.  Scale bars = 80 µm. 
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Fig. 2.4.  GFRα2 immunoreactivity associated with cholinergic innervation of right and 
left atrium.  Confocal images were obtained by sequential scanning of tissue sections 
that were double immunolabeled for CHT (red) and GFRα2 (green).  Many cholinergic 
nerves (CHT positive) are present throughout the right atrium (RA, A and D) and are 
especially abundant near the annulus of the tricuspid valve (TV, A).  Left atrium (LA) 
contains fewer cholinergic nerves than right atrium (compare D and G). Extensive 
colocalization of CHT and GFRα2 (yellow in right panels) was observed throughout the 
right atrium (A-C, level of TV; D-F more anterior level) and the left atrium (G-I).  A few 
CHT immunoreactive fibers did not exhibit GFRα2 immunoreactivity (arrows).  Open 
arrowhead in D indicates CHT innervation along blood vessel.  Solid arrowheads 
indicate examples of probable Schwann cell elements labeled for GFRα2 only.  
Asterisks indicate fiber bundles stained for GFRα2 only. Maximum projection images 
were obtained from 26 optical sections spanning a tissue thickness of 10 µm.  Scale 
bars = 80 µm. 
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Fig. 2.5.  GFRα2 immunoreactivity associated with cholinergic nerves in ventricular 
tissue. Confocal images were obtained by sequential scanning of tissue sections that 
were double immunolabeled for CHT and GFRα2 (A-F).  Low density of cholinergic 
nerves typical of right ventricular myocardium (RV) is seen in panel A along with 
cholinergic innervation of a coronary artery (*).  GFRα2 is colocalized with CHT in most 
of these fibers (A-C).  GFRα2 immunoreactivity is associated with the sparse 
cholinergic innervation of mouse left ventricle (LV, D-F) but occurs also in some non-
cholinergic processes (arrowheads).  Maximum projection images were obtained from 
26 optical sections spanning a tissue thickness of 10 µm.  Scale bar = 80 µm. 
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Fig. 2.6. GFRα2 immunoreactivity localized to S100 positive Schwann cells and their 
processes in  left ventricular wall (A-F) and S100 positive cell process located next to a 
VAChT labeled cholinergic nerve fiber in the  interatrial septum (G-I).  Confocal images 
were obtained by sequential scanning of tissue sections that were double labeled for 
S100 and either GFRα2 or VAChT.  GFRα2 and S100 immunoreactivity were 
extensively colocalized to Schwann cells (arrows) and their processes (arrowheads) in 
the left ventricular wall (A-F). Insert in A-C is a high magnification scan (63X oil 
objective) of the process indicated by a small box in the larger image.  Areas of 
colocalization are evident as a yellow to orange color in the merged images (C and F).  
High magnification scan of atrial cholinergic nerve fiber (G-I) shows that VAChT and 
S100 occur in very close proximity but are not colocalized as indicated by the near 
absence of yellow to orange areas in the merged image (I).  All panels are single optical 
sections. Asterisks mark the lumen of a blood vessel.  Scale bar = 80 µm in A-C; 20 µm 
in D-F; 5 µm in G-I and inserts. 
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Identification of Ret-immunoreactive cardiac nerve fibers 
  Immunolabeling of cardiac nerve fibers for Ret was weaker than that observed 
for GFRα2 in fibers and more difficult to detect than Ret labeling of neuronal cell bodies.  
Nevertheless, colocalization of Ret immunoreactivity with CHT was clearly observed at 
a few atrial sites including the sinus node (Fig. 2.7) and AV node (not shown).  This 
staining was obtained using tissue from hearts that were processed by brief perfusion 
with fixative prior to immersion fixation.  
 
 
 
 
Fig. 2.7.  Localization of Ret to cholinergic nerves in the sinus node.  Sequentially 
scanned confocal images show significant colocalization of Ret (green) with CHT (red) 
in cholinergic nerves of the mouse sinus node (A-C).  Maximum projection images were 
obtained from 26 optical sections spanning a tissue thickness of 10 µm.  Scale bar = 80 
µm. 
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Discussion 
  Our findings demonstrate that expression of NRTN continues in the adult 
mouse heart and that NRTN receptors are highly associated with intracardiac 
cholinergic neurons. A vast majority of the neurons in parasympathetic ganglia of the 
mouse heart exhibited the cholinergic phenotype (i.e., positive staining for ChAT), and 
over 90 percent of these cells expressed GFRα2 and Ret.  Our dual staining for CHT 
and GFRα2 provides the first detailed mapping of cholinergic innervation in the mouse 
heart and establishes that most cholinergic nerve fibers contain GFRα2 
immunoreactivity.  Some of these cholinergic nerve fibers, particularly those in the sinus 
and AV nodes, also exhibited Ret immunoreactivity, thereby presenting the possibility 
that NRTN could act at these sites to activate retrograde signaling mechanisms, which 
are characteristic of neurotrophic factors.  Additionally, immunolabeling for GFRα2 was 
detected in numerous Schwann cells that were associated with cholinergic and non-
cholinergic nerves in the adult mouse heart.  This finding suggests that these support 
cells many be an additional target for NRTN in the mature heart. 
  The expression of NRTN was detected by RT-PCR in the present study, and 
the identity of the PCR reaction product was confirmed by sequence analysis. This 
finding is consistent with the initial report on NRTN, which demonstrated NRTN mRNA 
in adult rat heart by RT-PCR analysis (Kotzbauer et al. 1996).  Previous reports that 
adult mouse heart lacks NRTN mRNA were based on evidence from in situ 
hybridization (Widenfalk et al. 1997; Golden et al. 1999), which has a lower sensitivity 
than RT-PCR.  Nevertheless, the sensitivity of in situ hybridization was sufficient to 
detect NRTN mRNA in mouse atria from E12-E18 (Golden et al. 1999), which suggests 
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that a higher level of expression occurs during development of the intracardiac nervous 
system.  This conclusion is consistent with the observation that Ret-/- mice, which die 
soon after birth, have approximately half the normal number of intracardiac neurons and 
reduced cholinergic innervation of the AV conducting system compared to wild-type 
controls (Hiltunen et al. 2000).  Our observation that NRTN is expressed by atrial tissue 
of adult mice supports the premise that this neurotrophic factor continues to influence 
cholinergic function in the mature heart since all cardiac cholinergic somata and a vast 
majority of their nerve fibers occur at this site.  In contrast, the detection of comparable 
NRTN expression in left ventricular myocardium was unexpected since this area of the 
mouse heart contains relatively few cholinergic nerves. However, our discovery that 
cardiac Schwann cells and their processes exhibit GFRα2 immunoreactivity suggests 
that NRTN also might have a trophic influence on these non-neuronal support cells, 
which are present in the left ventricular wall and throughout the remainder of the heart.  
  Cholinergic nerve fibers were identified in this study using an antibody to CHT, 
a protein that is specifically localized to cholinergic neurons (Kuhar et al. 1973; Suszkiw 
and Pilar 1976; Ferguson et al. 2003; Hoover et al. 2004).  This marker was used 
previously to map the cholinergic innervation of guinea pig hearts, where the vast 
majority of CHT immunoreactive nerve fibers occur in the sinus and AV nodes, 
conducting system and specific regions of right atrium (Hoover et al. 2004).  We found 
that cholinergic innervation of mouse heart was similar to that of guinea pig in that CHT 
immunoreactive nerves were most abundant in the sinus node and atrioventricular 
conducting system but sparse in working myocardium of ventricular septum and left 
ventricular wall.  However, the mouse differed from guinea pig by having more 
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cholinergic nerves in non-specialized regions of right and, to a lesser extent, left atrial 
myocardium, a low but significant number of cholinergic nerves in the right ventricular 
wall, and cholinergic innervation of blood vessels in atrial and ventricular myocardium.  
The distribution and relative regional abundance of GFRα2 immunoreactive nerve fibers 
paralleled the pattern of cholinergic innervation, and dual staining established that these 
markers were usually localized to the same processes throughout the heart and around 
coronary blood vessels.  These observations provide direct evidence for the association 
of GFRα2 with cholinergic nerve fibers in the mouse heart and expand on an earlier 
report that cholinergic nerve density is reduced in right ventricle and AV conducting 
system of Gfrα2 -/- mice (Hiltunen et al. 2000). Based on our findings, we predict that 
the cholinergic deficit of Gfrα2 -/- mice extends beyond these regions and likely includes 
the sinus node.  It should be noted that the widespread colocalization of GFRα2 and 
CHT to cholinergic nerve fibers in cardiac tissue is consistent with the presence of 
GFRα2 in a vast majority of ChAT immunoreactive neurons in the cardiac 
parasympathetic ganglia. Collectively, these observations imply that most cholinergic 
nerve fibers and cell bodies in the adult mouse heart retain the ability to specifically bind 
NRTN. 
 The presence of Ret is required for signaling by NRTN (Airaksinen and Saarma 
2002; Enomoto 2005) and our findings demonstrate that this crucial protein is present in 
over 90% of mouse intracardiac neurons.  We have also detected Ret immunoreactivity 
associated with some intracardiac nerve fibers. Although this staining was weaker than 
that observed for the neuronal somata, it was specifically localized to intracardiac nerve 
fibers and was most prominent in the sinus node, an important region not evaluated in 
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previous studies, and in the AV node. These results, when combined with our findings 
for GFRα2, demonstrate that both components of the NRTN receptor (i.e., ligand 
binding and signaling) are associated with cholinergic nerves that are known to regulate 
chronotropic and dromotropic functions of the heart.   
  While GFRα2 was commonly associated with cholinergic nerve fibers, a small 
population of intracardiac nerves stained for only CHT.  The absence of GFRα2 staining 
in some cholinergic nerve fibers is consistent with the fact that about 5% of intracardiac 
neurons that stained for PGP 9.5 did not exhibit immunoreactivity for the NRTN 
receptor.  Thus, a small population of intracardiac cholinergic neurons may be 
insensitive to NRTN. 
The presence of additional GFRα2 immunoreactivity in cardiac Schwann cells 
was established by demonstrating its colocalization with the glial cell marker S100.   
This finding is consistent with previous reports that GFRα2 is present in glial cells 
located in the mucosal and muscle layers of mouse small intestine (Rossi et al., 2003) 
and in glial cells located in several mouse pelvic organs (Wanigasekara et al. 2004).  
Results from our double labeling experiments indicate that GFRα2 positive cardiac 
Schwann cells can be associated with cholinergic and non-cholinergic nerve fibers. 
Likewise, previous investigators found that GFRα2 positive Schwann cells were located 
near cholinergic and non-cholinergic nerve fibers in pelvic organs (Wanigasekara et al. 
2004). Since Schwann cells and their processes occur in close proximity to some 
cholinergic nerve fibers and both of these cell types exhibit GFRα2 immunoreactivity, it 
is possible that NRTN affects some cholinergic neurons directly through neuronal 
receptors and indirectly through receptors on adjacent glial cells. 
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The continued expression of NRTN by adult mouse heart and the localization of 
NRTN receptors to most intracardiac neurons suggest that this neurotrophic factor is 
likely to have a tonic influence on cholinergic innervation of cardiac muscle and 
coronary vessels.  Specific effects of NRTN on established cardiac innervation require 
evaluation.  However, if NRTN affects cholinergic innervation in a fashion analogous to 
the influence of NGF on cardiac sympathetic nerves, NRTN might be required to 
maintain the structure, neurochemical phenotype and function of cholinergic neurons 
and their processes.  Support for this scenario comes from a recent study of sacral 
parasympathetic ganglion neurons of the rat (Wanigasekara and Keast 2005).  These 
investigators demonstrated that NRTN stimulated growth of dissociated neurons from 
this ganglion and initiated concentration dependent outgrowth and branching of 
neurites. Based on these considerations, it is possible that altered expression of NRTN 
might play a role in the development of cholinergic dysfunction, which often occurs in 
cardiac disease (Eckberg et al. 1971; La Rovere et al. 1998; Kuo et al. 1999; Singh et 
al. 2000).  
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Abstract 
Aims  Previous work has provided indirect evidence that the neurotrophic factor 
neurturin (NRTN) is required for normal cholinergic innervation of the heart.  This study 
used nrtn knockout (KO) and wild-type (WT) mice to determine the impact that nrtn 
deletion has on cardiac cholinergic neurons and nerve fibers and on cholinergic function 
in the adult heart. 
Methods  Immunohistochemistry, confocal microscopy, and quantitative image analysis 
were used to evaluate cardiac cholinergic structure directly.  Atrial acetylcholine (ACh) 
levels were determined as an indirect index of cholinergic innervation.  Cholinergic 
function was evaluated by measuring negative chronotropic responses to right vagal 
nerve stimulation in anesthetized mice and negative chronotropic responses of isolated 
atria to muscarinic agonists. 
Results  KO hearts contained only 35% the number of cholinergic neurons in  WT 
hearts, and the residual cholinergic neurons in KOs were 15% smaller in cross-sectional 
area.  Cholinergic nerve density at the sinoatrial node was reduced by 87% in KOs, but 
noradrenergic nerve density was unaffected.  Atrial ACh levels were substantially lower 
in KO mice (0.050 ±0.011 vs. 0.013 ± 0.004 pmol/μg protein; P<0.02) as expected from 
cholinergic neuron and nerve fiber deficits.  The maximum bradycardia evoked by vagal 
stimulation was reduced in KO mice (38 ± 6% vs. 69 ± 3% decrease at 20Hz; P<0.001), 
and negative chronotropic responses in KOs took longer to develop and fade.  In 
contrast to these deficits, isolated atria from KO mice had normal postjunctional 
sensitivity to carbachol and bethanechol. 
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Conclusions   These findings demonstrate that NRTN is essential for normal cardiac 
cholinergic innervation and cholinergic control of heart rate.  The presence of residual 
cardiac cholinergic neurons and vagal bradycardia in KO mice suggests that additional 
neurotrophic factors may influence this system. 
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Introduction 
Cardiac sympathetic neurons have a life-long requirement for nerve growth factor 
(NGF), which is a target-derived protein 1.  Retrograde transport and signaling by this 
neurotrophic factor are essential for survival of developing sympathetic neurons and for 
maintaining the structure and function of sympathetic nerves in the adult heart.  The 
latter requirement was manifest in recent findings implicating NGF in the remodeling of 
cardiac noradrenergic nerves that occurs in heart disease.  Specifically, reduced NGF 
levels in failing hearts were linked to the loss of sympathetic nerves and reduced 
norepinephrine re-uptake 2, 3, while elevated NGF levels around infarcted myocardium 
were associated with regional sympathetic hyperinnervation4 5, 6.  Loss of sympathetic 
nerves contributes to inotropic dysfunction in the failing heart, while sympathetic 
hyperinnervation increases risk for ventricular arrhythmias.  Far less is known about 
trophic factor requirements of cardiac parasympathetic neurons, but recent findings 
suggest that a protein named neurturin (NRTN) could serve as a crucial neurotrophic 
factor for these cells. 
NRTN is a member of the glial-cell-line-derived neurotrophic factor (GDNF) 
family, which contains three other ligands including GDNF 7, 8.  Members of this family 
signal through two-component receptors that comprise a specific ligand binding protein 
(GDNF family receptor α, GFRα) that couples to the transmembrane tyrosine kinase, 
Ret.  GDNF and NRTN exhibit preferential binding to GFRα1 and GFRα2, respectively, 
but some crosstalk can occur at higher concentrations of neurotrophic factor, allowing 
GDNF to signal through GFRα2/Ret complexes.  Both components of the NRTN 
receptor are expressed by cardiac parasympathetic neurons during development, and 
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deletion of the gene for either component (i.e., ret or gfrα2) disrupts development of 
cholinergic parasympathetic innervation of the heart 9.  Ret knockout mice die shortly 
after birth, but their hearts contain about half the number of cholinergic neurons present 
in wild-type (WT) mice 9. Deletion of gfrα2 produces a non-lethal phenotype, and hearts 
from these mice have significantly fewer cholinergic nerve fibers compared to hearts 
from WT mice 9.  Collectively, these experiments provide indirect evidence that NRTN 
has an essential role in establishing cholinergic innervation of the heart. 
 The requirement of NRTN for cholinergic innervation of the heart was assessed 
directly in this study by using nrtn (-/-) mice. Hearts from adult nrtn knockout (KO) and 
WT mice were evaluated for number and size of intrinsic cardiac neurons (ICNs), 
cholinergic and noradrenergic nerve densities at the sinoatrial (SA) node, and 
concentration of acetylcholine (ACh) in the atria.  Negative chronotropic responses to 
vagal nerve stimulation were measured in anesthetized mice, and postjunctional 
cholinergic responses were evaluated using spontaneously beating isolated atria.  Our 
findings delineate structural and functional cholinergic deficits that are present in the 
hearts of adult nrtn KO mice. 
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Material and methods 
Experimental animals 
Adult male C57BL/6 mice (16 weeks old; 24-30 g; Harlan, Indianapolis, IN) and 
16-week-old male nrtn KO mice 10 were used for this study.  Animal protocols were 
approved by the East Tennessee State University Animal Care and Use Committee and 
conformed to guidelines of the National Institutes of Health as published in the Guide for 
the Care and Use of Laboratory Animals (NIH publication No. 85-23, revised 1996).  
Animals were used at the minimum numbers required for reaching statistically valid 
conclusions.  
 
Tissue preparation for immunohistochemistry 
Animals were deeply anesthetized with 5% isoflurane and euthanized by cervical 
dislocation.  Hearts were removed rapidly and perfused through the ascending aorta 
with 3 ml of phosphate buffered saline (PBS) (pH 7.4, room temperature) followed by 3 
ml of cold fixative comprising 4% paraformaldehyde and 0.2% picric acid in PBS.  
Tissues were post-fixed another 2 h at 4°C, cryoprotected for 2 days in cold 20% 
sucrose/PBS, and sectioned in a Leica CM3050S cryostat (Leica Microsystems Inc., 
Bannockburn, IL).  Serial 16 μm short-axis sections were collected in six sets beginning 
at the most anterior aspect of the heart and ending at a level well into the ventricular 
myocardium.  Each set of slides was boxed separately, wrapped in aluminum foil, and 
stored at -80°C. 
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Immunohistochemistry 
Slide-mounted tissue sections were immunostained at room temperature as 
described previously 11 12.  Briefly, sections were washed in 0.1M PBS (pH 7.3), 
permeabilized with 0.4% Triton X-100 in PBS containing 0.5% bovine serum albumin 
(BSA), and blocked for 2 h in PBS containing 10% normal donkey serum (Jackson 
ImmunoResearch Laboratories, West Grove, PA), 1% BSA, and 0.4% Triton X-100.  
Tissues were then incubated for 15-18 h with two primary antisera generated in different 
species (Table 3.1), washed several times with 0.1M PBS, and incubated for 2 h with 
two species specific donkey secondary antibodies conjugated to Alexa Fluor 488 or 555 
(Molecular Probes, Eugene, OR). Secondary antibodies were used at a dilution of 
1:200.  After washing the sections several times with PBS, coverglasses were attached 
using Citifluor mounting medium (Ted Pella, Inc., Redding, CA) and sealed with clear 
nail polish.  Representative sections were routinely processed without primary 
antibodies (negative control).  In all cases, these negative control sections showed only 
background fluorescence. 
 
 Table 3.1 Primary antibodies for immunohistochemistry 
 
Antibody (abbreviation) Host Dilution Supplier Catalog Number 
Choline Acetyltransferase (ChAT) Goat 1:50 Millipore AB144P 
Tyrosine Hydroxylase (TH) Rabbit 1:1000 Pel-Freez P40101-0 
Vesicular Acetylcholine Transporter (VAChT) Goat 1:2000 Millipore AB1578 
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Confocal microscopy and image analysis 
Labeled tissue sections were viewed initially using an Olympus BX41 microscope 
(Olympus America Inc., Center Valley, PA), and regions of interest were selected for 
further evaluation by laser scanning confocal microscopy with a Leica TCS SP2 
confocal microscope system.  Specimens were scanned sequentially to avoid crosstalk 
between fluorochromes, and a maximum projection image was obtained from each 
series.  Negative controls for each fluorochrome were also scanned using the same 
parameter settings.  Images were exported into Corel Draw 11 and adjusted for 
brightness and contrast.  The total number of neurons present in each section was 
determined based on staining for the cholinergic marker choline acetyltransferase 
(ChAT), which was previously determined to be present in virtually all ICNs of the 
mouse 11.  Cell counts and cross-sectional areas were performed using Stereo 
Investigator/Workstation software (MicroBrightField, Williston, VT).  Cross-sectional 
area was measured only for neurons with the nucleus visible.  Cholinergic and 
noradrenergic nerve fibers were identified by dual staining for the vesicular ACh 
transporter (VAChT) and tyrosine hydroxylase (TH), respectively.  Quantitative 
evaluation of nerve fiber density was accomplished using Image J Software (National 
Institutes of Health, Bethesda, MD).  Average nerve density was determined from 
maximum projection confocal images obtained from 2 to 3 sections for each animal. 
 
ACh and choline assay 
Mice were anesthetized with 5% isoflurane, euthanized by cervical dislocation, 
and quickly irradiated for 5 sec with microwaves (1.45 KW, 2450 MHz) to denature 
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proteins and preclude enzymatic changes in ACh and choline levels 13.  The atria were 
removed, frozen in powdered dry ice, and weighed.  Frozen tissue samples were sent to 
the Center for Molecular Neuroscience Neurochemistry Core Lab at Vanderbilt 
University (Nashville, TN) for determination of ACh and choline concentrations by high 
performance liquid chromatography with detection using a post-column enzyme reactor.  
ACh and choline values were normalized to the protein concentration in samples.  
 
Vagal nerve stimulation 
Mice were anesthetized with 2% isoflurane, and needle electrodes were inserted 
subcutaneously into the right anterior and left posterior leg regions.  The 
electrocardiogram (ECG) was recorded using a Grass P55 A.C. preamplifier (Grass 
Technologies, West Warwick, RI), a PowerLab/8SP (ADInstruments, Colorado Springs, 
CO), and a computer running Chart software version 5.2 (ADInstruments, Colorado 
Springs, CO).  The right vagus nerve was isolated in the neck region, secured with a 
suture tie, and cut anterior to the tie.  A bipolar platinum electrode was placed on the 
distal end of the vagus nerve and kept in place with Kwik-Cast silicon sealant (World 
Precision Instruments, Sarasota, FL).  A Grass SD9 stimulator was used for nerve 
stimulation (10 ms, 1 V) at increasing frequencies from 0.5 to 20 Hz, allowing time for 
recovery between each 10 s stimulus train. Baseline heart rate, minimum rate during 
stimulation, and times required to reach minimum rate and return to baseline after 
ending stimulation were measured. 
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Concentration-response studies with isolated atrial preparations 
Mice were deeply anesthetized with 5% isoflurane and euthanized by cervical 
dislocation.  Hearts were removed and placed in oxygenated (95% O2, 5% CO2), cold 
(4°C) Krebs-Ringer bicarbonate buffer (pH 7.35 to 7.4) of the following composition (in 
mM): 120 NaCl, 4.7 KCl, 1.2 KH2PO4, 25 NaHCO3, 2.5 CaCl2, 1.2 MgCl2, and 11.1 D-
glucose.  The entire atrium was dissected from the ventricles, and each side was 
impaled with a small metal hook (#28 trout hooks) with attached 5-0 suture.  The left 
atrium was anchored to the bottom of a vertical support rod in a 10 mL tissue bath, and 
the right atrium was attached to a 25-g force transducer (World Precision Instruments, 
Sarasota, FL). Krebs-Ringer buffer in the tissue bath was oxygenated continuously and 
maintained at 37°C.  Spontaneous atrial contractions were recorded at a resting tension 
of 0.3 to 0.5 g using a ML224 Bridge Amplifier (ADInstruments, Colorado Springs, CO), 
a PowerLab/8SP, and a computer running Chart.  Postjunctional cholinergic sensitivity 
was evaluated by measuring changes in heart rate caused by cumulative additions of a 
muscarinic receptor agonist to the bath.  Concentration-response data were collected 
for two agonists, carbachol and bethanechol, in random order.  Atria were washed 
several times with buffer after testing the first agonist and given 10 to 15 min for 
recovery before evaluating responses to the second agonist.  Data were analyzed using 
Prism software version 4.01(GraphPad Software, La Jolla, CA) to determine the 
concentration of agonist that decreased heart rate by 50 percent (EC50). 
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Statistical analysis 
Data are presented as the mean ± SEM (n).  Pair wise comparisons of means 
were done using the Student’s t-test.  Frequency-response data from vagal stimulation 
were evaluated by two factor analysis of variance with repeated measures.  P<0.05 was 
considered significant.   
 
 Drugs 
  Bethanechol chloride (C5259) and carbachol chloride (C4382) were obtained 
from Sigma-Aldrich (St. Louis, MO). 
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Results 
Immunohistochemical and biochemical analysis 
Nrtn KO mice had about 65% fewer ICNs than WT mice, and the cross-sectional 
area of these neurons was significantly less (Fig. 3.1).  In accord with this deficit of 
ICNs, we found that cholinergic innervation of the SA node was reduced drastically in 
nrtn KO mice compared to WT (Fig. 3.2 A,B and Fig. 3.3 A).  Furthermore, visual 
examination of VAChT-stained sections showed a widespread deficit of cholinergic 
nerves in KO hearts, and this impression was supported by measurements of total atrial 
ACh concentration, which was reduced by 74% in KOs (Fig. 3.3 B).  Choline, a 
precursor of ACh, was unaffected.  In contrast to the marked cholinergic deficit in KO 
mice, the density of TH-immunoreactive, sympathetic nerves at the SA node was 
unaffected by deletion of nrtn (Fig. 3.2 C,D and Fig. 3.3 A). 
 
 
Figure 3.1 Relative abundance and size of ICNs in 16 week old male nrtn KO and WT 
mice.  (Left) KO mice had significantly fewer neurons, which were identified by 
immunolabeling for the cholinergic marker ChAT.  Data were obtained from one set of 
sections per mouse (i.e., one sixth of total sections), so the actual number of neurons 
per heart would be larger.  (Right) The cross-sectional area of ICNs was smaller in 
hearts from KO mice.  n=6 per group.  *P<0.05 vs. WT. 
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Figure 3.2   Representative images from confocal scans of SA nodes that were stained 
simultaneously for VAChT and TH to label cholinergic and noradrenergic nerves, 
respectively.  (A and B) VAChT-positive cholinergic nerve fibers were abundant in the 
SA node of WT mice but sparse in KO mice.  (C and D) TH staining of the same 
sections showed that noradrenergic nerves were less abundant than cholinergic nerves 
in the SA node but their density was similar in WT and KO mice.  Each panel shows a 
maximum projection image compiled from 21 optical sections that spanned an 8 μm 
thickness of tissue.  Scale bars = 150 μm. 
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Figure 3.3  Analysis of cholinergic and noradrenergic nerve fiber density in the SA node 
(A) and atrial ACh & choline concentrations (B) in nrtn KO and WT mice.  (A) Labeled 
tissue sections were scanned sequentially to obtain images of cholinergic (VAChT) and 
noradrenergic (TH) nerves.  Nerve fiber density was measured with Image J software 
and expressed as a percentage of the total nodal area.  n=6 per group.  *P<0.05 vs. 
WT.  (B) n=5 per group.  *P<0.05 vs. WT. 
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Negative chronotropic response to vagal nerve stimulation in vivo 
Negative chronotropic responses to right vagal stimulation were evaluated to 
assess the function of cardiac parasympathetic nerves in KO and WT mice.  No 
significant difference in baseline heart rate occurred between anesthetized KO and WT 
mice (WT: 594 ± 14 beat per min, n=6; KO: 640 ± 21 beats per min, n=5; P>0.05), and 
both strains had frequency-dependent decreases in heart rate during right vagal nerve 
stimulation (Fig. 3.4).  However, the maximum response to vagal stimulation was 
substantially smaller in KO mice.  We also observed that negative chronotropic 
responses to vagal stimulation and recovery from stimulation appeared slower in KO 
mice compared to WT (Fig. 3.5 A-D).  Specifically, KO mice took longer for heart rate to 
reach a nadir during vagal nerve stimulation and longer for return to baseline heart rate 
after stopping stimulation.  We quantified these effects by measuring the time for 
reaching minimum heart rate after vagal stimulation was initiated (onset) and the time 
for return of heart rate to baseline after vagal stimulation was stopped (offset).  Both the 
“onset” and “offset” were significantly longer in KO mice compared to WT mice (Fig. 3.5 
E). 
 
 
 
 
Figure 3.4 Negative chronotropic 
responses to right vagal nerve 
stimulation in anesthetized nrtn KO 
and WT mice.  n=6 for WT and 5 for 
KO.  F1,63=21.41 for treatment effect 
(KO versus WT). P=0.0012. 
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Figure 3.5 Time course of negative chronotropic responses to vagal stimulation.  (A-D) 
Representative recorder tracings showing the time course of heart rate responses to 10 
sec intervals of vagal stimulation at 8 and 20 Hz in WT and KO mice.  Vertical broken 
lines indicate the start and stop of vagal stimulation in each panel.  (E) Comparison of 
onset and offset times for vagal responses in WT and KO mice.  Onset was defined as 
the time from start of stimulation to reaching minimum rate.  Offset is the time required 
for return of heart rate to baseline after stopping stimulation. n=5 per group.  *P<0.05 
vs. WT. 
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Postjunctional cholinergic sensitivity 
Postjunctional muscarinic receptor sensitivity was evaluated in spontaneously 
beating isolated atria from KO and WT mice.  Cumulative concentration-response 
curves were constructed for two muscarinic receptor agonists (bethanechol and 
carbachol), and no differences were observed between atria from KO mice compared to 
WT mice (Fig. 3.6). Carbachol had a higher potency than bethanechol in both strains 
(carbachol –log EC50: 6.1 ± 0.1 for WT versus 6 ± 0.2 for KO, n=6 each; bethanechol –
log EC50: 4.7 ± 0.1 for WT versus 4.9 ± 0.1 for KO, n=6 each). 
 
Figure 3.6 Cumulative concentration-response curves for carbachol and bethanechol in 
isolated atria from nrtn KO and WT mice.  No difference in response occurred between 
atria from WT and KO mice.  Carbachol had a greater potency in both strains.  Baseline 
heart rates were not significantly different between groups (WT: 351 ± 21 beats per min; 
KO: 332 ± 5 beats per min; n=6 per group; P>0.05) 
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Discussion 
This work provides definitive evidence that NRTN plays a major role in the 
development of cardiac parasympathetic ganglia and cholinergic innervation of the 
heart.  Deletion of the NRTN gene produced a drastic reduction in the number of ICNs 
and corresponding decreases in total atrial ACh concentration and cholinergic nerve 
density at the SA node.  These structural and neurochemical deficits were accompanied 
by impaired negative chronotropic responses to direct activation of preganglionic 
cholinergic nerves by vagal stimulation.  Autonomic effects of NRTN deficiency at the 
heart were specific for cholinergic neurons since neither noradrenergic nerve density at 
the SA node nor postjunctional atrial sensitivity to muscarinic agonists was altered. 
 
Neurotrophic factors and cholinergic innervation of the heart 
The neurotrophin NGF has a vital role in the development and maintenance of 
cardiac noradrenergic innervation.  Little was known about the trophic factor 
requirements of ICNs, but the present findings and previous work with ret and gfrα2 KO 
mice 9 established that NRTN is essential for the development of a majority of ICNs and 
for normal cholinergic innervation of the mouse heart.  However, NRTN cannot be the 
sole neurotrophic factor affecting ICNs since a smaller subpopulation of ICNs and a 
reduced number of cholinergic nerves still developed in all three strains of KO mice (i.e., 
nrtn, ret, and gfrα2).  Contributions from other GDNF family ligands seems unlikely 
since gfrα1 and gfrα3 mRNAs were localized only to non-neuronal cells in cardiac 
parasympathetic ganglia of neonatal and three week old rats 9.  Also, hearts from E18 
ret KO mice did not show larger deficits in number of ICNs  than we observed in adult 
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nrtn KO mice 9, although it remains possible that neuronal loss would have been greater 
if these mice survived.  Neurotrophin-3 might serve as a neurotrophic factor for ICNs 
since transcripts for the neurotrophin-3 receptor (i.e., trkC) were identified in developing 
rat ICNs 14.  Additionally, we found that adult mouse ICNs exhibit trkA and p75 receptor 
immunoreactivity 12, suggesting that these cells may respond to NGF and other 
neurotrophins. 
      While cardiac sympathetic neurons in adults require NGF, it is unclear whether 
ICNs have a similar, life-long requirement for trophic support.  Evidence from studies of 
adult rat sacral parasympathetic neurons suggested that they retained their dependence 
on NRTN 15.  These parasympathetic neurons decreased in size after axotomy was 
performed to preclude retrograde transport of target-derived trophic factor.  In contrast, 
treatment of cultured sacral parasympathetic neurons with NRTN caused an increase in 
cross-sectional area of somata and stimulated neurite outgrowth.  Thus, NRTN still had 
a trophic action on adult sacral parasympathetic neurons.  The smaller size of KO ICNs 
compared to WT in the present study might be a consequence of NRTN deficiency.  
This possibility is supported by our previous work, which showed that nrtn is expressed 
in adult mouse atria and that adult mouse ICNs have both components of the NRTN 
receptor 11.    
 
Impaired cholinergic control of heart rate in nrtn KO mice 
 The substantial cholinergic nerve deficit that we observed in KO mice was 
associated with a marked impairment of negative chronotropic responses to right vagal 
nerve stimulation.  Not only was the magnitude of bradycardia reduced at each 
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stimulation frequency, but also the heart rate took longer to reach a nadir during nerve 
stimulation and to return to baseline after stimulation ended in the KO mice.  Delayed 
onset of maximum bradycardia could be a consequence of reduced cholinergic nerve 
density and the corresponding need for ACh to activate muscarinic receptors at a 
greater distance from the release sites.  While ACh is normally inactivated rapidly by 
acetylcholinesterase (AChE) that hydrolyzes ACh 16, this process may be prolonged in 
KO mice due to loss of AChE associated with cholinergic nerves.  Since AChE is 
localized primarily to cholinergic nerves in the heart 17, 18, reduced density of cholinergic 
nerves would also cause a deficit of AChE.  The same factor might explain the delayed 
recovery of heart rate in KO mice.  Decreased regional abundance of AChE within the 
SA node could prolong the survival of ACh and its ability to stimulate atrial muscarinic 
receptors.  In this case, diffusion of ACh could be important for terminating the 
bradycardia. 
 Interestingly, postjunctional sensitivity to muscarinic agonists was not affected in 
KO mice in spite of major deficits in cholinergic innervation and neurally-mediated 
cholinergic effects on heart rate.  It was possible that this condition might have triggered 
postjunctional supersensitivity due to a chronic reduction of cholinergic signaling at the 
SA node 19.  Lack of cholinergic supersensitivity might be a consequence of cardiac 
sympathetic dominance in mice as opposed to parasympathetic dominance in larger 
animals 20.  From this perspective, the reduced cholinergic innervation present in KO 
hearts may be sufficient to meet their needs.  It is also possible that C57BL/6 mice 
might have enough “spare” atrial muscarinic receptors to maintain cholinergic 
neurotransmission at a level sufficient to preclude development of supersensitivity. 
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Conclusions 
Our findings provide clear evidence that NRTN is essential for the development 
of normal cholinergic innervation of the heart and cholinergic control of heart rate.    
However, the specific role of NRTN in development of this system remains unknown.  Is 
NRTN required for migration of cholinergic precursor cells to the heart, innervation of 
atrial muscle (i.e., target-derived trophic factor), or does it serve both functions?  Our 
findings also show that NRTN cannot be the sole neurotrophic factor for development of 
cardiac cholinergic innervation.  Additional work is needed to identify other neurotrophic 
factors that influence the development of ICNs and determine if neurotrophic factors are 
required for the maintenance of cholinergic neurons and nerve fibers in the adult heart.  
Beyond these issues, the presence of well-defined structural and functional cholinergic 
deficits in the heart of NRTN knockout mice should make this strain a valuable tool for 
evaluating the role of cardiac parasympathetic nerves in disease. 
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ABSTRACT 
Background:  Cardiac autonomic neuropathy (CAN) occurs as a complication of 
diabetes mellitus (DM), resulting in imbalance of sympathetic and parasympathetic 
control of the heart.  This imbalance causes abnormalities in heart rate control and 
increases the risk of serious cardiac arrhythmias and sudden death. Several studies 
have examined the impact of diabetes on the cardiac sympathetic nervous system, but 
little is known about the effects on the cardiac parasympathetic system.  
Methods and Results:  In vivo electrocardiogram (ECG) recordings were obtained 
weekly from conscious control and streptozotocin (STZ)-induced diabetic mice for up to 
16 weeks post-injection. Over the 16 week time course, these recordings showed 
progressively decreased heart rate, increased short term heart rate variability, and 
increased duration of ST and rate corrected QT (QTc) intervals in diabetic mice. ECG 
recordings were supplemented with pharmacological testing using atropine and 
atenolol, which showed evidence of autonomic imbalance. Immunohistochemical 
analysis of atrial tissue stained for vesicular acetylcholine transporter revealed 
increased cholinergic nerve density at the sinoatrial node in diabetic mice compared to 
controls (14.9±1.2 vs. 8.9±0.8; p<0.01). Responses to right vagal nerve stimulation were 
blunted in 16-week diabetic mice with no change in postjunctional sensitivity of isolated 
atria to muscarinic agonists. 
Conclusions:  STZ-induced diabetes causes structural and functional remodeling of 
the cardiac parasympathetic nervous system in mice and these changes increase 
susceptibility to cardiac rhythm disturbances. The present study improves our 
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understanding of the impact that type 1 diabetes has on the cardiac parasympathetic 
nervous system and potential causes of arrhythmias associated with DM. 
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Introduction 
 Diabetes is a major cause of disability and mortality in the United States and 
worldwide.  It is a pervasive disease that causes a host of serious complications 
resulting from prolonged exposure to high levels of glucose and lipids (11). Diabetes 
can have a particularly devastating impact on the heart by causing cardiac pathology 
alone and in synergism with other diseases such as hypertension and atherosclerosis 
(34). Additionally, diabetes can further impair cardiac function by affecting the 
autonomic nerves that control heart rhythm (36). The presence of such cardiac 
autonomic neuropathy in diabetic patients increases their risk for life threatening 
ventricular arrhythmias and sudden death (23). Several epidemiological studies have 
provided evidence that diabetes also increases the risk for atrial fibrillation, which often 
impairs quality of life and can lead to stoke (23; 28). The mechanisms underlying these 
associations are undoubtedly complex and most likely involve pathophysiological 
remodeling of the autonomic nervous system and cardiac tissue.   
Several clinical studies have used heart rate variability (HRV) measurements to 
assess parasympathetic and sympathetic control of the sinus node in patients with and 
without DM (6; 27; 39). In a majority of these studies it was found that diabetics with 
decreased HRV were at increased risk for ventricular fibrillation and sudden death 
compared to non-diabetic patients and diabetic patients with normal HRV (27). Power 
spectral analysis of HRV has proven useful in evaluating cardiovascular autonomic 
function in several diseases, including diabetes (4; 6). Decreased HRV in the high 
frequency (HF) range indicates that there is a relative deficiency of parasympathetic 
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(cholinergic) input to the sinus node, and this change is sometimes viewed as reflecting 
sympathetic dominance throughout the heart (5).   
The autonomic nervous system and remodeling of atrial structure are both 
thought to play a role in the pathogenesis of atrial fibrillation. Assessing the impact of 
cholinergic remodeling on atrial function in diabetes requires consideration of structural 
and functional changes in cholinergic neurons and nerve fibers, postjunctional changes 
that influence response to acetylcholine (ACh), and the progressive nature of the 
disease.  A substantial body of evidence suggests that cholinergic mechanisms can 
have a particularly strong proarrhythmic influence on the atria (9; 37). Vagal stimulation 
and muscarinic (cholinergic) agonist drugs increase susceptibility to AF because they 
decrease the relative refractory period and action potential duration of atrial myocytes 
(43). Furthermore, ultrastructural changes in diabetic rabbit atria were accompanied by 
reduced sinus nodal automaticity, slowed conduction throughout the atria, and 
inhomogeneity of conduction (38).  Such conditions could form the substrate for atrial 
arrhythmias. While these findings are intriguing, effects of diabetes on atrial innervation 
were not evaluated.  
This study investigates the hypothesis that diabetes causes remodeling of the 
atrial cholinergic nervous system, which could make the atria more susceptible to 
arrhythmias. Experiments within this study provide a thorough analysis of the cardiac 
parasympathetic nervous system in mice with type 1 diabetes.   
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Materials and Methods 
  
Animals 
Adult male C57BL/6 mice (8 weeks old; 24-30g; Harlan, Indianapolis, IN) were 
used for this study.  Animal protocols were approved by the East Tennessee State 
University Committee on Animal Care and conformed to guidelines of the National 
Institutes of Health as published in the Guide for the Care and Use of Laboratory 
Animals (NIH publication No. 85-23, revised 1996). 
 
Induction of diabetes 
Diabetes was induced in adult male C57BL/6 mice at 8 weeks of age by multiple 
injections of streptozotocin (STZ, 50mg/kg; Sigma-Aldrich) according to a modified 
method based on work by Qi et al (31). STZ was dissolved in 0.1M sodium citrate buffer 
(pH 4-5) and administered by intraperitoneal (i.p.) injection within 10 min of preparing 
the solution. This time limit is crucial since STZ is very unstable in solution. Injections 
were given on five consecutive days, at the same time each day, after mice had been 
fasted for at least 6 h. Fasting for a minimum of 6 h is crucial for optimal effectiveness of 
STZ. STZ enters beta cells of the pancreas through the glucose transporter (35; 44); 
therefore, any glucose present at the time of injection would compete with STZ for the 
transporter and reduce STZ entry. Control mice received injections of citrate buffer 
vehicle only. Animal weights and non-fasting blood glucose levels were determined 
weekly to monitor progression of diabetes.  
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 Insulin treatment 
Effects of insulin were evaluated in one experiment via insulin therapy, beginning 
3 weeks after STZ injections. Half of the diabetic mice in this experiment were treated 
twice daily by subcutaneous injection of Novolin N insulin (0.5-2U; Novo Nordisk Inc., 
Princeton, NJ) for a total of 5 weeks. The remaining diabetic mice and non-diabetic 
controls were treated with diluent only (Eli Lilly and Company, Indianapolis, IN). 
Treatments were given at 7:00AM and 7:00PM daily based on non-fasting blood 
glucose levels. Insulin treated diabetic mice with non-fasting blood glucose of 
≤100mg/dL at time of treatment were not given insulin until the next scheduled 
treatment time.  In the event of hypoglycemia (non-fasting blood glucose of ≤60 mg/dL), 
corn syrup was administered orally to bring blood glucose levels quickly back to the 
normal range.   
 
Blood collection and analysis 
 Blood for glucose measurements was obtained by pricking the tip of the tail with 
a lancet between the hours of 7:00AM-10:00AM. The blood was collected directly onto a 
glucose testing strip and analyzed with a OneTouch Ultra2 glucose monitor (Life Scan 
Inc., Milpitas, CA). Larger quantities of blood (at least 8μL) were required for 
glycosylated hemoglobin A1c (HbA1c) measurement. Blood for analysis of HbA1c was 
drawn prior to termination by pricking the facial vein with a lancet and collected in 
heparin-coated Microcuvette CB300 tubes (Sarstedt, Newton, NC). These samples 
were analyzed by the Mouse Metabolic Pathophysiology Core at Vanderbilt University 
(Nashville, TN).   
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Tissue processing for histology 
Animals were deeply anesthetized with 5% isoflurane and euthanized by cervical 
dislocation. Hearts were removed rapidly and perfused through the ascending aorta with 
3 mL of phosphate buffered saline (PBS) (pH 7.4, room temperature) followed by 3 mL 
of cold fixative comprising 4% paraformaldehyde and 0.2% picric acid in PBS. Tissues 
were post-fixed another 2h at 4°C, cryoprotected for 2 days in cold 20% sucrose/PBS, 
and sectioned in a Leica cryostat/microtome. Serial 16μm short-axis sections were 
collected in six sets beginning at the most anterior aspect of the heart and ending at a 
level well into the ventricular myocardium. Each set of slides was boxed separately, 
wrapped in aluminum foil, and stored at -20°C.  
 
Immunohistochemistry 
Slide mounted tissue sections were immunostained at room temperature.  Briefly, 
sections were washed in 0.1M PBS (pH 7.3), permeabilized with 0.4% Triton X-100 in 
PBS containing 0.5% bovine serum albumin (BSA), and blocked for 2 h in PBS 
containing 10% normal donkey serum (Jackson ImmunoResearch Laboratories, West 
Grove, PA), 1% BSA, and 0.4% Triton X-100. Tissues were then incubated for 15-18 h 
with two primary antisera generated in different species (Table 4.1), washed several 
times with 0.1M PBS, and incubated for 2 h with two species specific donkey secondary 
antibodies conjugated to Alexa Fluor 488 or 555 (Molecular Probes, Eugene, OR). 
Secondary antibodies were used at a dilution of 1:200. After washing the sections 
several times with PBS, coverglasses were attached using Citifluor mounting medium 
(Ted Pella, Inc., Redding, CA) and sealed with clear nail polish. Representative sections 
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were routinely processed without primary antibodies (negative control). In all cases, 
these negative control sections showed only background fluorescence.  
 
  Table 4.1  Primary antibodies used for immunohistochemistry 
  
Antibody (abbreviation) Host Dilution Supplier Catalog number 
Choline acetyltransferase (ChAT) Goat 1:50 Chemicon (Temecula, CA) AB144P 
Vesicular ACh transporter (VAChT) Goat 1:2000 Chemicon AB1578 
Tyrosine hydroxylase (TH) Rabbit 1:1000 Pel-Freez (Rogers, AR) P40101-0 
 
Confocal Microscopy and image analysis 
Labeled tissue sections were viewed initially using an Olympus BX41 microscope 
and regions of interest were selected for further evaluation by laser scanning confocal 
microscopy with a Leica TCS SP2 confocal microscope system. Specimens were 
scanned sequentially to avoid crosstalk between fluorochromes, and a maximum 
projection image was obtained from each series of optical sections. Colocalization of 
immunolabels was evaluated in overlay images obtained from these scans.  Negative 
controls for each fluorochrome were also scanned using the same settings. Images 
were exported into Corel Draw 11 and adjusted for brightness and contrast. The total 
number of neurons present in each section was determined based on staining for the 
cholinergic marker choline acetyltransferase (ChAT), which was previously determined 
to be present in all intrinsic cardiac neurons of the mouse (21). Total cell counts and 
cross-sectional neuronal areas were measured using Stereo Investigator/Workstation 
software (MicroBrightField, Williston, VT).  Cholinergic and noradrenergic nerve fibers 
were identified by staining for vesicular ACh transporter (VAChT) and tyrosine 
hydroxylase (TH), respectively. Quantitative evaluation of nerve fiber density at the SAN 
in maximum projection images obtained from confocal microscopy was accomplished 
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using Image J Software (National Institutes of Health, Bethesda, MD). The SAN was 
outlined within each of 3 images obtained per animal, from which nerve density was 
analyzed by measuring the total number of pixels per image, and then isolating pixels 
containing nerve fibers only based on a threshold fluorescence level. Final values for 
nerve fibers are expressed as percent cholinergic/noradrenergic pixels out of total pixels 
(% total area).    
 
Electrocardiogram (ECG) acquisition and in vivo pharmacological testing 
 Lead II ECGs were obtained non-invasively using the ECGenie apparatus 
(Mouse Specifics, Inc., Boston, MA).  The ECGenie is a PowerLab-based system that 
acquires signal through disposable footpad electrodes located in the floor of a recording 
platform (8). Contact with two of three electrodes is required to obtain an ECG and 2-3 
seconds of recording (20-30 P-Q-R-S-T complexes) are sufficient for analysis. Several 
minutes of recording were collected from each mouse at every recording session with a 
constant segment of 20-30 complexes used for analysis. Raw ECG signals were 
analyzed using e-MOUSE software (Mouse Specifics, Inc., Boston, MA), which employs 
processing algorithms for peak detection, digital filtering, and correction of baseline for 
motion artifacts.  ECG was acquired weekly throughout the duration of the experiment. 
Heart rate (HR) was determined from the average of R-R intervals and short term heart 
rate variability (HRV) was based on the standard deviation of the R-R intervals. Power 
spectral analysis of ECG in the frequency domain was accomplished using low 
frequency (LF) and high frequency (HF) ranges that were previously published for 
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C57BL/6 mice (16). LF power range detection limits were 0.15-1.5 Hz and HF at 1.51-
5.0 Hz.  
 Assessment of autonomic control of the heart was accomplished through 
conscious ECG acquisition in conjunction with pharmacological testing.  ECG was 
recorded with the ECGenie apparatus before and after each of the following drug 
injections when mice were 8 and 16 weeks post-STZ injection. To block autonomic 
receptors and determine parasympathetic/sympathetic tone, atropine sulfate (5 mg/kg) 
or atenolol (5 mg/kg) was injected i.p. with at least 24 h between injections. Atropine 
and atenolol were also given in combination on a separate day in order to determine 
intrinsic HR.  For atropine and atropine/atenolol combination, ECGs were measured 
when the drug effect had reached a maximum (30 min).  For atenolol only, ECGs were 
measured at 20, 30, and 40 min post-injection. All drug doses and times to maximum 
effect were determined based on preliminary investigations. All injections were 
performed at the same time each day (8:00AM-10:00AM). 
 
Vagal nerve stimulation  
Diabetic and control mice were anesthetized with 2% isoflurane, and needle 
electrodes were inserted subcutaneously in the right anterior and left posterior leg 
regions. ECG was recorded using a Grass P55 A.C. preamplifier (Grass Technologies, 
West Warwick, RI), a PowerLab/8SP (ADInstruments, Colorado Springs, CO), and a 
computer running Chart software version 5.2 (ADInstruments, Colorado Springs, CO). 
The right vagus nerve was isolated in the neck region, secured with a suture tie, and cut 
anterior to the tie. A bipolar platinum electrode was placed on the distal end of the 
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vagus nerve and kept in place with Kwik-Cast silicon sealant (World Precision 
Instruments, Sarasota, FL). A Grass SD9 stimulator was used for nerve stimulation 
(10ms, 1-2V) at increasing frequencies from 0.5 to 20 Hz, allowing time for recovery 
between each 10s stimulus train. Baseline HR, ECG, and minimum HR during vagal 
stimulation were measured.  
 
Concentration-response studies with isolated atrial preparation 
Diabetic and control mice were deeply anesthetized with 5% isoflurane and 
euthanized by cervical dislocation. Hearts were removed and placed in oxygenated 
(95% O2, 5% CO2), cold (4°C) Krebs-Ringer bicarbonate buffer (pH 7.35-7.4) of the 
following composition (in mM): 120 NaCl, 4.7 KCl, 1.2 KH2PO4, 25 NaHCO3, 2.5 CaCl2, 
1.2 MgCl2, 11.1 D-glucose. Atria were dissected from the ventricles and impaled with 
small metal hooks (#28 trout hooks) with attached 5-0 suture.  The left atrium was 
anchored to the bottom of a vertical support rod in a 10mL tissue bath, and the right 
atrium was attached to a 25-g force transducer. The tissue baths contained oxygenated 
Krebs-Ringer solution maintained at 37°C with a thermostatically controlled circulating-
water bath (Isotemp 2013S; Fisher Scientific, Pittsburg, PA). Atria were placed under a 
resting tension of 0.5g and force of contraction was measured using a 25-g force 
transducer (World Precision Instruments, Sarasota, FL). Spontaneous atrial 
contractions were recorded using a ML224 Bridge Amplifier (ADInstruments, Colorado 
Springs, CO), a PowerLab/8SP, and a computer running Chart.  Postjunctional 
cholinergic sensitivity was evaluated by measuring changes in HR caused by 
cumulative additions of a muscarinic receptor agonist to the bath. Concentration 
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response data were collected for two agonists, carbachol and bethanechol, in random 
order.  Atria were washed several times with buffer after testing the first agonist and 
given 10 to 15 min for recovery before evaluating responses to the second agonist.  
Data were analyzed using Prism software version 4.01(GraphPad Software, La Jolla, 
CA) to determine the concentration of agonist that decreased HR by 50 percent (EC50). 
 
Drugs  
 Atenolol (A-7655), atropine sulfate (A-0257), bethanechol chloride (C-5259), 
carbachol chloride (C-4832) and STZ (85882) were from Sigma-Aldrich (St. Louis, MO).  
 
Statistical Analysis 
 Statistical analyses were performed using GraphPad Prism 4.01 (GraphPad 
Software, La Jolla, CA,). Values are presented as mean ± SEM, unless otherwise 
specified.  Values for n represent the number of animals/hearts used. A Student’s t-test 
was used for between group comparisons of HbA1c and nerve fiber density. A two-way 
ANOVA with repeated measures was used to compare all other differences between 
groups over time. This was followed by LSD post hoc testing when appropriate. 
Differences were considered significant at P<0.05. 
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Results 
 
General characteristics of STZ-treated mice  
Average body weight and blood glucose measurements did not differ between 
groups prior to injections and were monitored weekly to assess effects of diabetes. Mice 
injected with STZ had significantly reduced body weight gain when first measured at 2 
weeks post-injection (Control 25.5±0.5 grams vs. STZ 24.2±0.4 grams; P<0.05; Fig 4.1 
A). Mice with diabetes gained body weight slower than control mice for most of the 
study (2-way ANOVA; P<0.05). Non-fasting blood glucose levels were significantly 
increased in diabetic mice at 2 weeks (Control 144±5 mg/dL vs. STZ 376±15 mg/dL; 
P<0.05) (Fig 4.1 B) and subsequently remained over 400mg/dL for the entire 
experiment. HbA1c levels (%) were significantly increased in diabetic mice when 
measured at 8 and 16 weeks (Fig 4.1 C). 
 
 
 
 
 
 
Figure 4.1:  Characteristics of STZ treated mice. Effects of STZ on body weight (A) and 
blood glucose (B) over 16 weeks (Control: n=12; STZ: n=14). HbA1c levels (C) at 8 and 
16 week-post injection (n=6 for all).  *P<0.05 vs. control at same time. 
    
 
ECG analysis 
HR fell significantly within 2 weeks after administration of STZ (Control 803±4 vs. 
STZ 749±8; P<0.0001) and continued to decline throughout the experiment (2-way 
ANOVA P<0.0001; Fig 4.2 A). Analysis of the ECG waveform revealed that the ST and 
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rate corrected QT (QTc) intervals were significantly increased in diabetic mice (2-way 
ANOVA P<0.05 for both; Fig. 4.2 B,C). QT dispersion was also significantly increased in 
diabetic animals (2-way ANOVA P<0.05; data not shown). Raw ECG waveforms from 
diabetic mice (Fig. 4.2 E) showed increased short term HRV compared to control (Fig. 
4.2 D), suggesting the presence of sinus arrhythmias. Power spectral analysis of the 
ECG showed that diabetic mice had significantly decreased HF power (Fig. 4.2 F) and 
increased LF power (Fig. 4.2 G) when first examined 2 weeks post-STZ treatment 
(Student’s t-test P<0.01 for both). These changes were evident at most subsequent time 
points as well (2-way ANOVA P<0.0001 for both; Fig. 4.2 F,G). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2:  ECG analysis of heart rate. ECG derived heart rate (A), ST segment length 
(B) and QTc interval (C). Representative ECG from non-anesthetized 14 week post-
injected control (D) and diabetic (E) mouse. Power spectral analysis of HF (F) and LF 
(G) power.  (Control:  n=12; STZ: n=14). 
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Pharmacologic assessment of HR control 
Effects of treatment with the muscarinic antagonist atropine on HR and HRV at 8 
weeks were no different in control and diabetic mice (Student’s t-test; P>0.05). At 16 
weeks, there was no change in overall HR with atropine (Student’s t-test; P>0.05), but 
short term HRV (defined in bpm as standard deviation of RR interval), which was 
significantly elevated in diabetic animals at baseline (5.93±0.5 vs. 16.3±4.7 bpm, 
P<0.05), was significantly decreased in diabetic mice 30 min after the injection (P<0.05) 
(Fig. 4.3 A). At 8 and 16 weeks, diabetes enhanced effects of β1-adrenergic receptor 
blockade on HR and HRV with atenolol (2-way ANOVA P<0.01) (Fig. 4.3 B). Effects of 
combined blockade with atropine and atenolol on HR (Fig. 4.3 C) and HRV (not shown) 
were not different at 8 or 16 weeks, indicating no change in intrinsic HR at either time.  
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Figure 4.3: Pharmacological assessment of HR control. HR and HRV responses in 
control and diabetic mice at 16 weeks to pharmacological challenge with atropine (A) 
and atenolol at 16 weeks (B). HR responses (intrinsic heart rate) to combination 
blockade of atropine and atenolol at 8 and 16 weeks (C). (A: n=16 and B,C: n=9 per 
group; *P<0.05 compared to control at same time point; #P<0.05 compared to 
baseline). 
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Effect of STZ on intracardiac neurons and nerve fibers 
 
Intracardiac ganglia (ICG) are located primarily in epicardial connective tissue 
along the posterior surface of the atria and in interatrial septum. These ganglia are 
innervated by the vagus nerve and send projections to discrete areas of the heart, 
including the sinoatrial node (SAN). Quantitative evaluation of ICG in 16-week post-
injected control and STZ-treated mice showed that all neurons exhibited ChAT 
immunoreactivity. The total number of intracardiac neurons did not differ between the 
two groups.  However, the cross-sectional area of neurons in STZ-treated mice was 
about 10% smaller compared to controls (249±7μm2 versus 223±4μm2; n=6 each; 
P<0.05).  
Quantitative evaluation of staining at the SAN revealed increased cholinergic 
nerve fiber density in STZ-treated mice compared to controls at both times studied (Fig. 
4.4). Insulin therapy prevented this increase in 8 week STZ-treated mice (Fig 4.4 C, F). 
There was no significant change in SAN noradrenergic fiber density at either of the 
times studied (8 weeks: Control 3.7±0.7 vs. STZ 3.5±0.5; 16 weeks: Control 2.5±0.4 vs. 
STZ 3.0±0.8; both P>0.05 Student’s t-test). 
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Figure 4.4: Cholinergic nerve fiber density in the SAN is increased in STZ-treated mice. 
Maximum projection confocal images of sections of SAN immunostained for VAChT in 
(A) 8wk control, (B) 8wk STZ, (C) 8wk insulin-treated STZ, (D) 16wk control and (E) 
16wk STZ hearts. (F) Quantitative analysis of cholinergic fiber density in the SAN at 8 
and 16 weeks post-injection. Maximum projections images were obtained from 21 
optical sections spanning a tissue thickness of 8µm. Scale bar 150µm.  *P<0.05 vs. 
Control at same time; #P<0.05 vs. STZ at same time (n=6 per group). 
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Effects of Vagal Nerve Stimulation  
 
Negative chronotropic responses to right vagal nerve stimulation were measured 
in control and diabetic mice at 8- and 16-week post-injection to assess the function of 
cardiac parasympathetic nerves. There was no difference in baseline HR between 
groups before vagal stimulation at either time studied (8wk: 561±21 bpm vs. 570±29 
bpm, P>0.05; 16wk: 572±31 bpm vs. 581±22 bpm, P>0.05). Vagal nerve stimulation 
caused frequency dependent decreases in HR in all animals (Fig. 4.5). There was a 
trend toward suppression of vagal nerve response in diabetic animals at 8 weeks (2-
way ANOVA P>0.05; Fig 4.5 A), which became significant with 16 weeks of diabetes 
(Fig 4.5 B; P<0.03). Specifically at 16 weeks, responses to stimulation frequencies of 1-
12Hz were significantly suppressed in diabetic mice (P<0.05). 
 
 
Figure 4.5: Negative chronotropic responses to right vagal nerve stimulation in 
anesthetized 8 (A) and 16 week (B) post-injected control and STZ-induced diabetic 
mice. (n=6 per group).  
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Concentration-response studies with isolated atrial preparations 
Cumulative concentration-response curves were constructed for the direct-acting 
cholinergic agonists at 8 and 16 weeks post-injection. No difference in intrinsic rate 
amongst isolated atria was observed among any of the groups prior to addition of 
agonists (data not shown; ANOVA, P>0.05). No differences in HR response to 
cumulative additions of either agonist were observed at 8 or 16 weeks (Fig 4.6). 
Carbachol had a higher potency than bethanechol in both groups at each time tested 
(carbachol: 8 weeks –log EC50: 6.1 ±0.1 for control vs.  6.1±0.1 for STZ, 16 weeks –log 
EC50: 5.8±0.2 for control vs. 6.1±0.1, for STZ ; bethanechol: 8 weeks –log EC50: 
4.6±0.2 for control vs. 4.8±0.2 for STZ, 16 weeks –log EC50: 4.5±0.2 for control vs. 
4.6±0.1 for STZ; n=6 each). 
 
 
 
 
 
 
 
 
Figure 4.6:  Cumulative concentration-response curves for carbachol and bethanechol 
in isolated atria from 8 (A) and 16 week (B) post-injected control and STZ-induced 
diabetic mice.  
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Discussion 
This study represents the first evaluation of the impact of STZ-induced type 1 DM 
on the cardiac parasympathetic nervous system in mice. Our results demonstrate that 
structure and function of this system are remodeled when challenged with STZ-induced 
diabetes. In mice with severe type 1 diabetes, cholinergic nerves within the SAN 
undergo sprouting, which can be prevented with insulin treatment. Short-term HRV was 
increased in diabetic mice which could be attenuated by muscarinic receptor blockade. 
Removal of sympathetic contribution to heart rate with β1-adrenergic blockade resulted 
in lower heart rate in diabetic mice. In spite of this evidence for enhanced cholinergic 
function, diabetic mice had a decreased response to direct vagal nerve stimulation with 
no change in postjunctional sensitivity of atria to muscarinic agonists. Power spectral 
analysis of the diabetic ECG revealed an imbalance in autonomic control of heart rate. 
Altogether, these data suggest that type 1 diabetes causes either a defect at the 
intracardiac ganglia or further upstream, including transmission from the central nervous 
system.   
 
Using STZ as a model of type 1 diabetes in rodents 
Previous studies using animal models of type 1 diabetes have most commonly 
been performed in STZ-induced rats (7; 10; 12; 14; 15). Our model of STZ-induced 
diabetes produces more severe hyperglycemia than in rats, thus preventing the mice 
from living long enough to examine the long-term effects of the disease. Therefore, 
comparisons of studies within the literature have somewhat conflicting conclusions. The 
current study employs a multiple low-dose (50mg/kg) STZ-induced model in male 
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C57BL/6 mice.  In our model, non-fasting blood glucose levels rose to nearly 500 mg/dL 
within 8 weeks and remain above this level. Severity of diabetes was also evident from 
HbA1c measurements, which were consistently around 5% for controls, but were almost 
12% in diabetic mice at 8 weeks and over 14% by 16 weeks. By 16 weeks, these mice 
are beginning to show a decline in overall physical condition from the severe 
hyperglycemia, which was evident by significant weight loss and reduced activity and 
grooming. The standard diabetes induction method in rats, a single dose of 50-65 mg/kg 
STZ, produces only moderately high levels of blood glucose ranging from 267-465 
mg/dL by 10 weeks (12; 15) and around 356 mg/dL after almost 1 year (7).  
 
Preganglionic cholinergic function 
 In human diabetics, decreased HRV is considered to be the earliest sign of 
cardiac dysfunction. This, in combination with decreased cardiac baroreflex observed in 
type 1 diabetics, has been attributed to cardiac parasympathetic denervation (42). In 
human atrial appendage, ACh release and choline uptake were decreased in diabetic 
patients with late complications (neuropathy, nephropathy), compared to those without, 
indicating time dependency of pathological changes (30), which would be consistent 
with a loss of nerves (22; 42). In our study with severe type 1 diabetic mice, we found 
reductions in responses to VNS at 16, but not 8, weeks of diabetes with increased 
sprouting of cholinergic nerves in the SAN at both times. This implies that 
postganglionic nerves are preserved during early diabetes, suggesting a defect in 
preganglionic transmission that could be related to loss of those nerves. Intracardiac 
neuronal cell bodies appear normal in diabetic mice, but are ~10% smaller in size than 
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control. In rats with a year of STZ diabetes, neurons were still present and appeared 
normal, but nerves, likely preganglionic, were showing degeneration (17). Electron 
microscopic studies on alloxan-treated rats showed a loss of atrial post-ganglionic 
cholinergic nerves and their function after 7-8 months of diabetes (41). These data 
suggest there are progressive changes in the neural axis with postganglionic function 
being preserved early on in diabetes, with deficits primarily residing upstream. From 
other studies in animals with less severe forms of diabetes, it also appears that a central 
defect occurs earlier, since responses to vagal stimulation are preserved but baroreflex 
sensitivity is decreased (10; 13; 24-26).   
 
Postganglionic cholinergic function 
 Postganglionic cholinergic nerve function was not directly evaluated in type 1 
diabetic mice, but two lines of evidence suggest this is largely intact. First of all, we 
observed increased short term HRV in 16-week diabetic mice that was normalized by 
blockade of muscarinic receptors with atropine. Additionally, treatment with atenolol, to 
block sympathetic effects on heart rate, resulted in a significantly lower heart rate in 
diabetic mice at 8 and 16 weeks. These results, if anything, suggest enhanced 
cholinergic function and parasympathetic tone, which is consistent with the cholinergic 
hyperinnervation we observed in sections of SAN from 8- and 16-week diabetic mouse 
hearts. Furthermore, the increase in cholinergic innervation in diabetic SAN is supported 
by evidence from a study using STZ rats that where found to have increased levels of 
ChAT and ACh in atrium at 8 weeks (1). Secondly, responses of the SAN to direct 
stimulation of post-junctional muscarinic receptors were no different in normal mice and 
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severe diabetic mice. Previous studies in long-term human diabetics theorized that 
postjunctional supersensitivity might be linked to decreased baroreflex response that 
would be expected to result in a compensatory increase in muscarinic receptors (32), 
but there is no actual evidence for this increase. There is, however, evidence that such 
changes may occur with long-term experimental diabetes (10; 19). These data suggest 
as diabetes progresses there may be a compensatory increase in muscarinic receptor 
sensitivity. If there were a decrease in cholinergic signaling to the heart or a decrease in 
nerve function, then compensatory supersensitivity of post-junctional muscarinic 
receptors would have been expected, but this did not occur in our model. Additionally, in 
our model, there is no driving force for these types of changes because functional 
evidence suggests that receptors are getting activated, if anything more than normal. 
 
HR, HRV and potential for arrhythmias 
 Diabetic mice examined in this study had decreased baseline HR with increased 
short term HRV and sinus arrhythmias. Decreased HR has been documented in STZ 
diabetic rats, which was attributed in part to decreased body temperature because it 
and HR were normalized with insulin treatment (14). This decrease in rate was 
accompanied by increased short term HRV and respiratory sinus arrhythmias in a 
majority of diabetic mice in our model. As mentioned previously, the increased HRV and 
sinus arrhythmias were cholinergic in nature because they were blocked with atropine. 
Decrease in heart rate and arrhythmias were only observed in the in vivo experiments 
and not in isolated atrial preparations, suggestive of asynchronous input into the system 
as apposed to dysfunction in pacemaker or conduction through the atria. In addition, 
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results from power spectral analysis of the ECG were indicative of autonomic imbalance 
based on a shift in high and low frequency parameters. However, there were limitations 
to the ECG measurements contained within this study in that they were only 
representative of short-term changes in HR and HRV, as compared to those measured 
long term (over a 24 hour time period). 
 Diabetic patients also have a higher incidence of ventricular arrhythmias and 
sudden cardiac death, especially when combined with cardiac autonomic neuropathy 
(3). Clinical assessment of risk for ventricular arrhythmias involves examination of the 
ECG recording, particularly the QT segment. Abnormal prolongation of the QT or any 
variant of the QT interval, including QTc and QT dispersion, has been associated with 
higher risk for developing ventricular arrhythmias (2; 3; 20; 33; 40). The presence of a 
prolonged QT interval reflects an increase in myocyte recovery phase (46) following 
excitation of the ventricles (2). Significant increases in QT, QTc and QT dispersion were 
observed in diabetic mice in the present study as well as in rats and rabbits with STZ-
induced diabetes (18; 29; 45; 46).  
 
Conclusions 
The data presented in this study show that type 1 diabetes impacts structure and 
function of the cardiac parasympathetic nervous system.  Multiple components of this 
system appear to be affected, suggesting disconnect between cholinergic activity at the 
heart level and central control of heart rate. Parasympathetic remodeling of the atria is 
likely to result in nerves firing in a less synchronous fashion which may contribute to the 
autonomic dysfunction and increased atrial arrhythmogenesis commonly associated 
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with diabetes. Further studies into the origination of the mechanisms responsible for the 
cholinergic remodeling will assist in determining how to prevent the remodeling from 
occuring.    
 103
Acknowledgements 
 This work was supported by National Heart, Lung and Blood Institute Grant HL-
54633 and a Grant-in-Aid from American Heart Association (AHA) Southeast Affiliate 
awarded to Dr. Donald Hoover, as well as AHA Pre-doctoral Fellowship Grant and 
ETSU Graduate Council Research Grant both awarded to Abigail Mabe. 
.   
 104
References 
 1.  Akiyama N, Okumura K, Watanabe Y, Hashimoto H, Ito T, Ogawa K and Satake T. 
Altered acetylcholine and norepinephrine concentrations in diabetic rat hearts. 
Role of parasympathetic nervous system in diabetic cardiomyopathy. Diabetes 38: 
231-236, 1989. 
 2.  Arildsen H, May O, Christiansen EH and Damsgaard EM. Increased QT dispersion 
in patients with insulin-dependent diabetes mellitus. Int J Cardiol 71: 235-242, 
1999. 
 3.  Aytemir K, Aksoyek S, Ozer N, Gurlek A and Oto A. QT dispersion and autonomic 
nervous system function in patients with type 1 diabetes. Int J Cardiol 65: 45-50, 
1998. 
 4.  Bellavere F, Balzani I, De MG, Carraro M, Carenza P, Cobelli C and Thomaseth K. 
Power spectral analysis of heart-rate variations improves assessment of diabetic 
cardiac autonomic neuropathy. Diabetes 41: 633-640, 1992. 
 5.  Bernardi L, Rossi M, Soffiantino F, Marti G, Ricordi L, Finardi G and Fratino P. 
Cross correlation of heart rate and respiration versus deep breathing. Assessment 
of new test of cardiac autonomic function in diabetes. Diabetes 38: 589-596, 1989. 
 6.  Burger AJ, Charlamb M and Sherman HB. Circadian patterns of heart rate 
variability in normals, chronic stable angina and diabetes mellitus. Int J Cardiol 71: 
41-48, 1999. 
 7.  Chang KS and Lund DD. Alterations in the baroreceptor reflex control of heart rate 
in streptozotocin diabetic rats. J Mol Cell Cardiol 18: 617-624, 1986. 
 8.  Chu V, Otero JM, Lopez O, Morgan JP, Amende I and Hampton TG. Method for 
non-invasively recording electrocardiograms in conscious mice. BMC Physiol 1: 6, 
2001. 
 9.  Coumel P. Autonomic influences in atrial tachyarrhythmias. J Cardiovasc 
Electrophysiol 7: 999-1007, 1996. 
 10.  Dall'Ago P, D'Agord SB, da S, V, Werner J, da Silva Soares PP, De AK and 
Irigoyen MC. Parasympathetic dysfunction is associated with baroreflex and 
chemoreflex impairment in streptozotocin-induced diabetes in rats. Auton Neurosci 
131: 28-35, 2007. 
 11.  Davis SN and Granner DK. Insulin, oral hypoglycemic agents, and the 
pharmacology of the endocrine pancreas. In: Goodman & Gilman's The 
Pharmacological Basis of Therapeutics, edited by Hardman JG, Limbird LE and 
Gilman AG.  New York: McGraw-Hill, 2001, p. 1679-1714. 
 105
 12.  Ganguly PK, Dhalla KS, Innes IR, Beamish RE and Dhalla NS. Altered 
norepinephrine turnover and metabolism in diabetic cardiomyopathy. Circ Res 59: 
684-693, 1986. 
 13.  Gu H, Epstein PN, Li L, Wurster RD and Cheng ZJ. Functional changes in 
baroreceptor afferent, central and efferent components of the baroreflex circuitry in 
type 1 diabetic mice (OVE26). Neuroscience 152: 741-752, 2008. 
 14.  Howarth FC, Jacobson M, Shafiullah M and Adeghate E. Effects of insulin 
treatment on heart rhythm, body temperature and physical activity in 
streptozotocin-induced diabetic rat. Clin Exp Pharmacol Physiol 33: 327-331, 2006. 
 15.  Joffe II, Travers KE, Perreault-Micale CL, Hampton T, Katz SE, Morgan JP and 
Douglas PS. Abnormal cardiac function in the streptozotocin-induced non-insulin-
dependent diabetic rat: noninvasive assessment with doppler echocardiography 
and contribution of the nitric oxide pathway. J Am Coll Cardiol 34: 2111-2119, 
1999. 
 16.  Just A, Faulhaber J and Ehmke H. Autonomic cardiovascular control in conscious 
mice. Am J Physiol Regul Integr Comp Physiol 279: R2214-R2221, 2000. 
 17.  Kamal AA, Tay SS and Wong WC. The cardiac ganglia in streptozotocin-induced 
diabetic rats. Arch Histol Cytol 54: 41-49, 1991. 
 18.  Lenhard MJ and Maser RE. Sharing the pain. Diabetes Care 26: 1606-1607, 2003. 
 19.  Liu TP, Juang SW, Cheng JT and Tong YC. The role of sorbitol pathway and 
treatment effect of aldose reductase inhibitor ONO2235 in the up-regulation of 
cardiac M2-muscarinic receptors in streptozotocin-induced diabetic rats. Neurosci 
Lett 383: 131-135, 2005. 
 20.  Lykke JA, Tarnow L, Parving HH and Hilsted J. A combined abnormality in heart 
rate variation and QT corrected interval is a strong predictor of cardiovascular 
death in type 1 diabetes. Scand J Clin Lab Invest 1-6, 2008. 
 21.  Mabe AM, Hoard JL, Duffourc MM and Hoover DB. Localization of cholinergic 
innervation and neurturin receptors in adult mouse heart and expression of the 
neurturin gene. Cell Tissue Res 326: 57-67, 2006. 
 22.  Maser RE and Lenhard MJ. Cardiovascular autonomic neuropathy due to diabetes 
mellitus: clinical manifestations, consequences, and treatment. J Clin Endocrinol 
Metab 90: 5896-5903, 2005. 
 23.  Maser RE, Mitchell BD, Vinik AI and Freeman R. The association between 
cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a 
meta-analysis. Diabetes Care 26: 1895-1901, 2003. 
 106
 24.  McDowell TS, Chapleau MW, Hajduczok G and Abboud FM. Baroreflex 
dysfunction in diabetes mellitus. I. Selective impairment of parasympathetic control 
of heart rate. Am J Physiol 266: H235-H243, 1994. 
 25.  McDowell TS, Hajduczok G, Abboud FM and Chapleau MW. Baroreflex 
dysfunction in diabetes mellitus. II. Site of baroreflex impairment in diabetic rabbits. 
Am J Physiol 266: H244-H249, 1994. 
 26.  Mesangeau D, Laude D and Elghozi JL. Early detection of cardiovascular 
autonomic neuropathy in diabetic pigs using blood pressure and heart rate 
variability. Cardiovasc Res 45: 889-899, 2000. 
 27.  Molon G, Targher G, Costa A, Bertolini L, Barbieri E and Zenari L. Measurement of 
microvolt T-wave alternans, a new arrhythmic risk stratification test, in Type 2 
diabetic patients without clinical cardiovascular disease. Diabet Med 23: 207-210, 
2006. 
 28.  Movahed MR, Hashemzadeh M and Jamal MM. Increased prevalence of third-
degree atrioventricular block in patients with type II diabetes mellitus. Chest 128: 
2611-2614, 2005. 
 29.  Navaratnam S and Khatter JC. Influence of the diabetic state on digitalis-induced 
cardiac arrhythmias in rat. Arch Int Pharmacodyn Ther 301: 151-164, 1989. 
 30.  Oberhauser V, Schwertfeger E, Rutz T, Beyersdorf F and Rump LC. Acetylcholine 
release in human heart atrium: influence of muscarinic autoreceptors, diabetes, 
and age. Circulation 103: 1638-1643, 2001. 
 31.  Qi Z, Fujita H, Jin J, Davis LS, Wang Y, Fogo AB and Breyer MD. Characterization 
of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 54: 
2628-2637, 2005. 
 32.  Richardson MD, Kilts JD and Kwatra MM. Increased expression of Gi-coupled 
muscarinic acetylcholine receptor and Gi in atrium of elderly diabetic subjects. 
Diabetes 53: 2392-2396, 2004. 
 33.  Rossing P, Breum L, Major-Pedersen A, Sato A, Winding H, Pietersen A, Kastrup J 
and Parving HH. Prolonged QTc interval predicts mortality in patients with Type 1 
diabetes mellitus. Diabet Med 18: 199-205, 2001. 
 34.  Sander GE, Wilklow FE and Giles TD. Heart failure in diabetes mellitus: causal and 
treatment considerations. Minerva Cardioangiol 52: 491-503, 2004. 
 35.  Schnedl WJ, Ferber S, Johnson JH and Newgard CB. STZ transport and 
cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes 43: 1326-
1333, 1994. 
 107
 36.  Schramm E, Wagner M, Nellessen U and Inselmann G. Ultrastructural changes of 
human cardiac atrial nerve endings in diabetes mellitus. Eur J Clin Invest 30: 311-
316, 2000. 
 37.  Schuessler RB, Grayson TM, Bromberg BI, Cox JL and Boineau JP. 
Cholinergically mediated tachyarrhythmias induced by a single extra stimulus in 
the isolated canine right atrium. Circ Res 71: 1254-1267, 1992. 
 38.  Senges J, Brachmann J, Pelzer D, Hasslacher C, Weihe E and Kubler W. Altered 
cardiac automaticity and conduction in experimental diabetes mellitus. J Mol Cell 
Cardiol 12: 1341-1351, 1980. 
 39.  Singh JP, Larson MG, O'Donnell CJ, Wilson PF, Tsuji H, Lloyd-Jones DM and 
Levy D. Association of hyperglycemia with reduced heart rate variability (The 
Framingham Heart Study). Am J Cardiol 86: 309-312, 2000. 
 40.  Suys BE, Huybrechts SJ, de WD, Op De BL, Matthys D, Van OB, Du Caju MV and 
Rooman RP. QTc interval prolongation and QTc dispersion in children and 
adolescents with type 1 diabetes. J Pediatr 141: 59-63, 2002. 
 41.  Tomlinson DR and Yusof AP. Autonomic neuropathy in the alloxan-diabetic rat. J 
Auton Pharmacol 3: 257-263, 1983. 
 42.  Vinik AI and Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 
115: 387-397, 2007. 
 43.  Wakimoto H, Maguire CT, Kovoor P, Hammer PE, Gehrmann J, Triedman JK and 
Berul CI. Induction of atrial tachycardia and fibrillation in the mouse heart. 
Cardiovasc Res 50: 463-473, 2001. 
 44.  Wang Z and Gleichmann H. GLUT2 in pancreatic islets: crucial target molecule in 
diabetes induced with multiple low doses of streptozotocin in mice. Diabetes 47: 
50-56, 1998. 
 45.  Zhang L, Parratt JR, Beastall GH, Pyne NJ and Furman BL. Streptozotocin 
diabetes protects against arrhythmias in rat isolated hearts: role of hypothyroidism. 
Eur J Pharmacol 435: 269-276, 2002. 
 46.  Zhang Y, Xiao J, Lin H, Luo X, Wang H, Bai Y, Wang J, Zhang H, Yang B and 
Wang Z. Ionic mechanisms underlying abnormal QT prolongation and the 
associated arrhythmias in diabetic rabbits: a role of rapid delayed rectifier K+ 
current. Cell Physiol Biochem 19: 225-238, 2007. 
 
  
 
 108
CHAPTER 5 
 
 
SUMMARY 
 
 This study represents the first detailed mapping of cholinergic neuroanatomy of 
the mouse heart based on immunohistochemical staining.  Cholinergic innervation of 
the mouse heart is largely focused in the atrium and conducting system, which is 
consistent with rat (Schafer et al. 1998; Xu et al. 2006) and guinea pig (Hoover et al. 
2004). In contrast to larger animals and humans, there is very little amount of 
cholinergic innervation in the ventricles of the mouse heart. This work definitively 
demonstrates that NRTN plays a major role in the development of cardiac 
parasympathetic ganglia and cholinergic innervation of the mouse heart. The presence 
of NRTN and its receptors in adult mouse atria suggests a continued requirement for 
this neurotrophic factor in the adult heart. We’ve also shown that the cardiac cholinergic 
nervous system in mouse undergoes structural and functional remodeling when 
challenged with STZ-induced diabetes. Cholinergic nerves in diabetic hearts undergo 
extensive sprouting at the SAN with no change in the number of intracardiac neurons. 
Diabetic cholinergic function appears to be enhanced, based on pharmacological 
testing, despite decreased response to direct vagal nerve stimulation.  Evidence also 
suggests that diabetic mice have an imbalance in autonomic control of HR.  The latter 
findings suggest that disruption of central input into intrinsic cardiac ganglia also 
contributes to the neuropathology of type 1 diabetes. 
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Species Dependent Variation in the Distribution of Cholinergic Nerves and their Role in 
Cardiac Regulation 
 
Cholinergic innervation of the mouse heart is similar to that of guinea pig in that 
the cholinergic nerves are more abundant in the sinus node and AV conducting system 
but sparse in ventricles. However, the mouse differs from guinea pig by having more 
cholinergic nerves in non-specialized regions of the right and, to a lesser extent, left 
atrial myocardium, a low but significant number of cholinergic nerves in the right 
ventricular wall, and cholinergic innervation of the blood vessels in the atrial and 
ventricular myocardium. Anatomical evidence of cholinergic innervation in larger 
animals and humans is fairly sparse with the majority of studies focusing on 
parasympathetic function. In larger animals, such as dogs, and in humans, which have 
a lower resting heart rate, functional studies suggest there is more cholinergic 
innervation in the ventricles. Even within different strains of mice we have observed 
variation in cholinergic nerve density. For example, NON LtJ mice, which are an inbred 
white mouse control strain, have significantly less cholinergic nerve fiber density at the 
SAN compared to C57BL/6 mice (see Appendix A1). The decreased cholinergic 
innervation parallels their increased atrial postjunctional muscarinic sensitivity (see 
Appendix A2).  
 
Neurotrophic Influences on Cholinergic Neurons 
 Cardiac sympathetic neurons in adults require NGF; however, it is unclear 
whether ICNs have a similar, life-long requirement for trophic support.  The present 
findings and previous work with ret and gfrα2 KO mice (Hiltunen et al. 2000) established 
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that NRTN has an essential role in the development of a majority of ICNs and for normal 
cholinergic innervation of the mouse heart. However, NRTN cannot be the sole 
neurotrophic factor influencing ICNs because a small number of ICNs and cholinergic 
nerves still developed in all three strains of KO mice (i.e., nrtn, ret, and gfrα2). 
Neurotrophin-3 might serve as a neurotrophic factor for ICNs because expression of its 
receptor, trkC, was found in rat ICNs (Hiltunen et al. 1996).  Additionally, we found that 
adult mouse ICNs exhibit trkA and p75 receptor immunoreactivity (Hoard et al. 2008), 
suggesting that these cells may respond to NGF and other neurotrophins. 
 
The Nature of Cholinergic Remodeling in Diabetes and How it Affects Function 
In our study we found no evidence for the loss of intracardiac cholinergic neurons 
as a result of type 1 diabetes in mice, which is consistent with results obtained with one-
year STZ-treated rats showing that cardiac neurons appeared normal (Kamal et al. 
1991). STZ-treated rats also had degeneration within preganglionic cholinergic nerve 
fibers surrounding the cardiac neurons (Kamal et al. 1991). Alloxan-treated 7-8 month 
diabetic rats exhibited cardiac nerve degeneration as well (Tomlinson and Yusof 1983). 
These observations were similar to those seen in studies where NGF was depleted from 
sympathetic neuronal ganglia, resulting in a loss in nerve processes but not in neurons 
(Ruit et al. 1990), and suggests possible involvement of neurotrophic factors.  
Our study is the first to use true cholinergic markers to examine the effect of 
diabetes on murine cardiac parasympathetic innervation. We found cholinergic 
hyperinnervation in the SA node of diabetic mouse atrium at 8 and 16 weeks, with no 
change in adrenergic innervation. However, it is possible that a longer term of diabetes 
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with chronic severe glucose impairment may be required for cardiac cholinergic 
innervation in the atrium to be lost, as suggested by studies in rat (Kamal et al. 
1991;Tomlinson and Yusof 1983). Unfortunately, we were unable to examine mice that 
had been diabetic for longer than 4 months due to the severity of the disease in this 
model; therefore, the duration of cholinergic hyperinnervation seen in diabetic mice is 
unknown.  The status of cholinergic innervation in the atrium of diabetic rats is unknown 
early on in diabetes, but biochemical evidence of increased ChAT and ACh at 8 weeks 
in diabetic rat atrium (Akiyama et al. 1989) is consistent with the hyperinnervation found 
in our studies. The mechanism for the parasympathetic hyperinnervation is uncertain, 
but increased availability of neurotrophic factors seems likely based on previous studies 
with NGF and sympathetic cardiac innervation (Ieda et al. 2006).  
Diabetic mice in our studies exhibited evidence of cholinergic functional 
remodeling as well.  Short term HRV was increased in diabetic mice indicating 
enhanced cholinergic tone. This finding was further supported by pharmacological 
evaluation wherein HRV was normalized with atropine and HR was further decreased 
with atenolol, which is consistent with our observed hyperinnervation of the atrium. On 
the other hand, ECG power spectral analysis of HF power and responses to direct vagal 
nerve stimulation were both decreased indicating preganglionic nerve dysfunction. The 
apparent incompatibility of these results suggests that cholinergic activity is enhanced at 
the heart level, but central regulation of heart rate is impaired. A substantial body of 
evidence suggests that cholinergic mechanisms can have a particularly strong 
proarrhythmic influence on the atria (Coumel 1996; Schuessler et al. 1992). 
Furthermore, diabetics have been shown to have increased risk for atrial arrhythmias 
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(Movahed et al. 2005). Therefore, our findings suggest that structural and functional 
remodeling of cardiac cholinergic innervation could be a contributing factor to the 
increased arrhythmogenesis seen in diabetic patients. Additionally, it is well known that 
the intracardiac nervous system has a high degree of complexity, which could be a 
factor which enables activity independent of central input to the heart.   
 
Topics for Future Studies 
Like any research study, this one has identified topics for further investigation. The 
following are some of the problems that still need to be resolved: 
 
o Identify other neurotrophic factors that influence the development of intracardiac 
neurons and determine if neurotrophic factors are required for the maintenance 
of cholinergic neurons and nerve fibers in the adult heart.  
o Investigate mechanisms responsible for cardiac cholinergic hyperinnervation 
observed in type 1 diabetic mouse atrium, including involvement of NRTN or 
other neurotrophic factors. 
o Investigate central remodeling occurring with type 1 diabetes to clarify the 
disconnect between cholinergic activity at the heart level and central control of 
heart rate.   
o Determine if more extensive remodeling occurs with longer duration of type 1 
diabetes in mouse because studies in diabetic rats have shown evidence for 
preganglionic cholinergic nerve degeneration and increased postjunctional 
muscarinic supersensitivity. 
o Determine if type 1 diabetic mice have increased susceptibility to atrial 
tachycardia through use of tissue stimulation studies in isolated atrium. 
o Examine cholinergic remodeling in mice with Type 2 Diabetes because this type 
of diabetes is more prevalent.  
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APPENDIX 
 
 
Comparison of NON LtJ and C57BL/6 
 
 
 
 
Figure A1: Comparison of 
cholinergic nerve fiber density 
at the SAN in NONLtJ and 
C57BL/6 mice. (*P<0.05 n=7 
each) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2: Comparison of 
cumulative concentration-
response curves for 
carbachol in isolated atria 
from NONLtJ and C57BL/6 
mice. (-log EC50s: 
NONLtJ  6.4±0.08 (n=4) 
and C57BL/6  5.713±0.07 
(n=6); P<0.05).  
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